6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

The polarity and specificity of SARS-CoV2 -specific T lymphocyte responses determine disease susceptibility

3 Jean-Eudes FAHRNER^{1,2,3,4}, Agathe CARRIER^{*2,3}, Lyon COVID study group^{*5-8}, Eric DE SOUSA*13, Damien DRUBAY*2,12, Agathe DUBUISSON*2,3, Arthur GERAUD*2,9,10, Anne-4 5 Gaëlle GOUBET*1,2,3, Gladys FERRERE*2,3, Yacine HADDAD*2,3, Imran LAHMAR*1,2,3, MAZZENGA^{*2,3}, Cléa MELENOTTE^{*2,3,11}, Marion PICARD^{*2,3}, Cassandra 6 Marine 7 THELEMAQUE^{*2,3}, Luigi CERBONE^{2,9}, Joana R. LÉRIAS¹³, Ariane LAPARRA^{2,9,10}, Alice 8 BERNARD^{2,9,10}, Benoît KLOECKNER^{2,3}, Marianne GAZZANO^{2,3}, François-Xavier 9 DANLOS^{1,2,3}, Safae TERRISSE^{2,3}, Carolina ALVES COSTA SILVA^{1,2,3}, Eugenie PIZZATO^{2,3}, 10 Caroline FLAMENT^{2,3}, Pierre LY^{2,3}, Eric TARTOUR^{14,15}, Lydia MEZIANI², Abdelhakim 11 AHMED-BELKACEM¹⁶, Makoto MIYARA¹⁷, Guy GOROCHOV¹⁷, Fabrice BARLESI^{2,9,18}, 12 Caroline PRADON^{2,19,20}, Emmanuelle GALLOIS^{2,21}, Fanny POMMERET^{2,22}, Emeline COLOMBA^{2,9}, Pernelle LAVAUD^{2,9}, Eric DEUTSCH^{1,2,23,24}, Bertrand GACHOT^{2,25}, Jean-13 14 Philippe SPANO²⁶, Mansouria $MERAD^{2,27}$, Florian $SCOTTE^{2,22}$, Aurélien MARABELLE^{1,2,3,9,10,28}, Frank GRISCELLI^{2,21,29,30,31}, Jean-Yves BLAY^{32,33,34}, Jean-Charles 15 16 SORIA^{1,2}, Fabrice ANDRE^{1,2,9,35}, Mathieu CHEVALIER³⁶, Sophie CAILLAT-ZUCMAN³⁷, Florence FENOLLAR³⁸, Bernard LA SCOLA³⁸, Guido KROEMER^{39,40,41,42,43,44}, Markus 17 MAEURER**13,45,46,47, Lisa DEROSA**1,2,3,9, and Laurence ZITVOGEL**1,2,3,28. 18

19

^{*}Co-second authors, listed in alphabetical order, have equally contributed to this work.

21 **Co-last authors have equally contributed to this work.

22

23 ¹Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.

- ²Gustave Roussy, Villejuif, France
- ³Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy,
- 26 Villejuif, France.
- ⁴Transgene S.A., Illkirch-Graffenstaden, France
- 28 ⁵Open Innovation & Partnerships (OIP), bioMérieux S.A., Marcy l'Etoile, France. R&D –
- 29 Immunoassay, bioMérieux S.A., Marcy l'Etoile, France.
- 30 ⁶Joint Research Unit Hospices Civils de Lyon-bioMérieux, Civils Hospices of Lyon, Lyon
- 31 Sud Hospital, Pierre-Bénite, France.
- 32 ⁷International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS
- 33 UMR 5308, ENS, UCBL, Lyon, France.
- ⁸Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
- 35 ⁹Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France.
- ¹⁰Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy,
- 37 Villejuif, France
- 38 ¹¹Aix-Marseille Université, Institut de Recherche pour le Développement, Assistance
- Publique Hôpitaux de Marseille, Microbes Evolution Phylogeny and Infections, Marseille,
 France.
- 41 ¹²Département de Biostatistique et d'Epidémiologie, Gustave Roussy, Université Paris-Saclay,
- 42 Villejuif, France.
- 43 ¹³ImmunoTherapy/ImmunoSurgery, Champalimaud Centre for the Unknown, Lisboa,
- 44 Portugal.
- 45 ¹⁴Department of Immunology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
- 46 ¹⁵PARCC, INSERM U970
- 47 ¹⁶Univ Paris Est Creteil, INSERM U955, IMRB, Creteil, France.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

- 2
- 48 ¹⁷ Sorbonne Université/Institut National de la Santé et de la Recherche Médicale, U1135,
- 49 Centre d'Immunologie et des Maladies Infectieuses, Hôpital Pitié-Salpêtrière, Assistance
- 50 Publique Hôpitaux de Paris, Paris, France.
- 51 ¹⁸Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France.
- ¹⁹Centre de ressources biologiques, ET-EXTRA, Gustave Roussy, Villejuif, France.
- ⁵³ ²⁰Département de Biologie Médicale et Pathologie Médicales, service de biochimie, Gustave
- 54 Roussy, Villejuif, France.
- 55 ²¹Département de Biologie Médicale et Pathologie Médicales, service de microbiologie,
- 56 Gustave Roussy, Villejuif, France.
- 57 ²²Département Interdisciplinaire d'Organisation des Parcours Patients, Gustave Roussy,
- 58 Villejuif, France.
- ²³Institut National de la Santé et de la Recherche Médicale, U1030, Gustave Roussy, Villejuif,
 France.
- 61 ²⁴Département de Radiothérapie, Gustave Roussy, Villejuif, France.
- 62 ²⁵Service de Pathologie Infectieuse, Gustave Roussy, Villejuif, France.
- 63 ²⁶Department of Medical Oncology, Pitié-Salpétrière Hospital, APHP, Sorbonne Université,
- 64 Paris, France
- 65 ²⁷Service de médecine aigue d'urgence en cancérologie, Gustave Roussy, Villejuif, France.
- ²⁸Center of clinical investigations BIOTHERIS, INSERM CIC1428, Gustave Roussy,
- 67 Villejuif, France
- ²⁹Institut National de la Santé et de la Recherche Médicale UMR935/UA9, Université Paris Saclay, Villejuif, France.
- ³⁰INGESTEM National IPSC Infrastructure, Université de Paris-Saclay, Villejuif, France.
- 71 ³¹Université de Paris, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France.
- ³²Centre Léon Bérard, Lyon, France.
- 73 ³³Université Claude Bernard, Lyon, France.
- 74 ³⁴Unicancer, Paris, France.
- ³⁵Institut National de la Santé et de la Recherche Médicale, U981, Gustave Roussy, Villejuif,
- France.
- ³⁶INSERM UMR 976, Institut de Recherche Saint-Louis, Université de Paris, Paris, France.
- 78 ³⁷Laboratory of Immunology, AP-HP, Hôpital Saint Louis, INSERM UMR1149, Université
- 79 de Paris, Paris, France.
- 80 ³⁸Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France.
- 81 ³⁹Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer,
- 82 Université de Paris, Sorbonne Université, Inserm U1138, Institut Universitaire de France,
- 83 Paris, France.
- ⁴⁰Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Université Paris
- 85 Saclay, Villejuif, France.
- 86 ⁴¹Pôle de Biologie, Hôpital Européen George Pompidou, Assistance Publique Hôpitaux de
- 87 Paris, Paris, France.
- 88 ⁴²Université de Paris, Paris, France.
- ⁴³Department of Women's and Children's Health, Karolinska Institute, Karolinska University
- 90 Hospital, Stockholm, Sweden.
- 91 ⁴⁴Suzhou Institute for Systems Biology, Chinese Academy of Medical Sciences, Suzhou,
- 92 China.
- 93 ⁴⁵Medizinische Klinik, Johannes Gutenberg University Mainz, Germany.
- ⁴⁶Division of Infection and Immunity, University College London, London, UK.
- ⁴⁷NIHR Biomedical Research Centre, University College London Hospitals, London, UK.
- 96

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

- 97 *Corresponding author:*
- 98 Laurence ZITVOGEL, MD, PhD, Full Professor
- 99 University Paris Saclay,
- 100 Gustave Roussy Cancer Center,
- 101 114 rue Edouard Vaillant,
- 102 94805 Villejuif Cedex, France
- 103 Telephone: +33 1 42 11 50 41
- 104 E-mail: laurence.zitvogel@gustaveroussy.fr
- 105
- 106 Keywords: TH2/TH1 paradigm, cancer, COVID-19, S1-RBD, viral variants, T cell memory

107 Abstract

108 Optimal vaccination and immunotherapy against coronavirus disease COVID-19 relies on the 109 in-depth comprehension of immune responses determining the individual susceptibility to be

- 110 infected by SARS-CoV-2 and to develop severe disease. We characterized the polarity and 111 specificity of circulating SARS-CoV-2-specific T cell responses against whole virus lysates or 112 186 unique peptides derived from the SARS-CoV-2 or SARS-CoV-1 ORFeome on 296 cancer-113 bearing and 86 cancer-free individuals who were either from the pre-COVID-19 era (67 114 individuals) or contemporary COVID-19-free (237 individuals) or who developed COVID-19 115 (78 individuals) in 2020/21. The ratio between the prototypic T helper 1 (TH1) cytokine, 116 interleukin-2, and the prototypic T helper 2 (TH2) cytokine, interleukin-5 (IL-5), released from 117 SARS-CoV-2-specific memory T cells measured in early 2020, among SARS-CoV-2-negative 118 persons, was associated with the susceptibility of these individuals to develop PCR-detectable 119 SARS-CoV-2 infection in late 2020 or 2021. Of note, T cells from individuals who recovered 120 after SARS-CoV-2 re-infection spontaneously produced elevated levels of IL-5 and secreted 121 the immunosuppressive TH2 cytokine interleukin-10 in response to SARS-CoV-2 lysate, 122 suggesting that TH2 responses to SARS-CoV-2 are inadequate. Moreover, individuals 123 susceptible to SARS-CoV-2 infection exhibited a deficit in the TH1 peptide repertoire affecting 124 the highly mutated receptor binding domain (RBD) amino acids (331-525) of the spike protein. 125 Finally, current vaccines successfully triggered anti-RBD specific TH1 responses in 88% 126 healthy subjects that were negative prior to immunization. These findings indicate that COVID-127 19 protection relies on TH1 cell immunity against SARS-CoV-2 S1-RBD which in turn likely 128 drives the phylogenetic escape of the virus. The next generation of COVID-19 vaccines should 129 elicit high-avidity TH1 (rather than TH2)-like T cell responses against the RBD domain of
- 130 current and emerging viral variants.
- 131

132

133 Introduction

134

The emergence and spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease 2019, have resulted in devastating morbidities and socioeconomic disruption. The development of community protective immunity relies on long-term B and T cell memory responses to SARS-CoV-2. This can be achieved through viral infection [1] or by vaccination [2-4]. Reports on rapidly decreasing

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

spike- and nucleocapsid-specific antibody titers post-COVID-19 infection [5] or reduced neutralizing capacity of vaccine-induced antibodies against viral escape variants compared to the ancestral SARS-CoV-2 strain [6, 7] have shed doubts on the importance of humoral immunity as a standalone response. In contrast, T cell immunity was identified as an important determinant of recovery and long-term protection against SARS-CoV-1, even 17 years after infection [8-11].

146 The TH1 versus TH2 concept suggests that modulation of the relative contribution of TH1 or TH2 cytokines regulates the balance between immune protection against microbes and 147 148 immunopathology [12-14]. TH1 cells (as well as cytotoxic T cells with a similar cytokine 149 pattern referred to as TC1 cells) produce IFNy, IL-2, and TNFB, promote macrophage 150 activation, antibody-dependent cell cytotoxicity, delayed type hypersensitivity, and opsonizing 151 and complement-fixing IgG2a antibody production [12]. Therefore, TH1/TC1 cells drive the 152 phagocyte-dependent host response and are pivotal for antiviral responses [13, 14]. In contrast, 153 TH2 (and TC2) cells produce IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13, providing optimal help 154 for both humoral responses and mucosal immunity, through the production of mast cell and 155 eosinophil growth and differentiation factors, thus contributing to antiparasitic and allergic 156 reactions. Naïve T cell differentiation to distinct TH fates is guided by inputs integrated from 157 TCR affinity, CD25 expression, costimulatory molecules, and innate cell-derived cytokines 158 [15].

159 SARS-CoV-2-specific T cell immunity plays a key role during acute COVID-19, and up to eight months after convalescence [16-20]. Indeed, functional T cell responses remain 160 increased in both frequency and intensity up to six months post-infection [5]. They are mainly 161 162 directed against spike, membrane and nucleocapsid proteins, and have been studied in greater detail by single cell sequencing in a limited number of patients. Memory TH1/TC1 T cells 163 164 specific for SARS-CoV-2 and follicular T helper cells (TFH) cells have been detected in mild 165 cases [21]. However, cases of reinfection have been reported [22] raising questions on the 166 clinical significance of T cell polarization and peptide repertoire specificities against current 167 viral variants. Moreover, pioneering reports suggest that, before SARS-CoV-2 became prevalent (i.e., before 2020), some individuals exhibit immune responses, mainly among CD4⁺ 168 169 T cells, against SARS-CoV-1 nucleocapsid (NC) and ORF1a/b, or common cold coronaviruses 170 (CCC) spike and nucleocapsid proteins that are cross-reactive with SARS-CoV-2 [9, 23, 24, 171 80]. However, the relevance of CCC or SARS-CoV-1-specific memory T cells for effective protection against the current pandemic remains questionable [21, 25]. 172

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

In the present report, we studied SARS-CoV-2 –specific T cell responses in 382 cancerbearing or cancer-free subjects, and prospectively followed up 227 COVID-free individuals to understand which T cell polarity and peptide repertoire may convey resistance to COVID-19. We found that a SARS-CoV-2-specific IL-2/IL-5 lymphokine ratio<1 conferred susceptibility to COVID-19 infection or re-infection, coinciding with defective TH1 recognition of the receptor binding domain (RBD) of the spike protein, likely affecting viral evolution by selecting for new antigenic variants.

- 180
- 181 **Results**
- 182

183 Effector and memory T cell responses against coronaviruses during COVID-19 infection 184

185 We conducted a cross-sectional analysis of the functional T cell responses across several 186 cohorts of healthy individuals and cancer patients enrolled in various prospective studies (Table 187 S1-S2). First, an epidemiological observational study (Figure 1A) aimed at defining the 188 incidence, prevalence, and severity of COVID-19 in cancer patients, opened during the first 189 surge of the pandemic at Gustave Roussy [26]. While the majority of the 227 enrolled cancer 190 patients stayed COVID-19-free, we could analyze T cell responses during the acute phase of 191 SARS-COV-2 infection (n=24) or during convalescence post-COVID-19 (n=28). All the other 192 "unexposed" (COVID-19-negative) cancer patients were analyzed anytime between mid-March 193 and September 2020 (Table S1, Figure 1A). In parallel, we analyzed 22 cancer-free, COVID-194 19-free healthy volunteers (HV) from 15 distinct families at the same time as their family members were in convalescent phase for COVID-19 (n=26) (Figure 2A, Table S3). A third 195 196 cohort of 67 individuals from the pre-COVID-19 era (leukocytes frozen between 1999 and 197 2018) were either HV from the blood bank (n=38) or cancer patients (n=29) recruited in the 198 context of clinical trials [27-30] (Table S1, Figure 1A).

199 T cell responses directed against viral lysates from the historic SARS-CoV-2 strain 200 IHUMI846 (CoV-2) isolated in early 2020 or two endemic common cold coronaviruses (CCC), 201 OC43 and 229E, were evaluated by an *in vitro* stimulation assay (IVS). As outlined in Figure 202 1B, in a first step, autologous dendritic cells (DC) were differentiated from monocytes for 72hrs 203 in GM-CSF+IFNa2b. DC were spinoculated with viral particles from heat-inactivated viral 204 lysates and activated with LPS in a second step. Peripheral blood lymphocytes (PBL) kept in 205 low-dose IL-2 during this first step were then stimulated for 48hrs by activated DC after 206 removal of LPS (Figure 1B). The specific viral lysates were compared to supernatants from cell

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

6

207 lines permissive for viral replication (such as Vero E6 for SARS-CoV-2, HCT8 for OC43, 208 MRC5 for 229E). Negative controls were unloaded DC/PBL cell cocultures, while positive 209 controls were PBL stimulated with anti-CD3/anti-CD28 -coated beads. The cytokines 210 accumulating in the supernatants were analyzed by means of a 12-plex flow cytometry-based 211 bead assay (Figure S1A). In this cross-presentation assay, SARS-CoV-2-related IFNy or IL-2 secretions from PBL depended on MHC class I and MHC class II molecules, as shown using 212 213 specific neutralizing antibodies (Figure S1B). We calculated the ratio of cytokine release by dividing interleukin concentrations following exposure to viral lysates by those obtained with 214 215 the respective control supernatants, to ascribe the specificity of the reactivity to SARS-CoV-2 216 or to CCC antigens for each subject.

217 First, we characterized the intensity and the quality of PBL responses elicited at the acute phase of SARS-CoV-2 infection (day of symptom onset and/or first positive qPCR of the 218 219 oropharyngeal swab and/or serology), between mid-March and mid-May 2020 in 24 interpretable tests performed on COVID-19⁺ subjects compared to a cohort of 304 controls 220 221 (Table S2). Robust SARS-CoV-2 specific IL-2 and IFNy release, most likely caused by 222 TH1/TC1 cells, and the secretion of IL-4. IL-5 and IL-10, most likely mediated by TH2/TC2 223 effector T cells, were detectable, and were dominated by IL-2 and IL-5, respectively (Figure 224 1C, Figure 1D). An antiviral response, characterized by type 1 IFN release, was also prevalent (Figure S1C), as previously detected by single cell transcriptomics in the subset of transitional 225 226 memory CD4⁺ T cells [21]. Of note, COVID-19 infection did not reactivate CCC-specific T 227 cell responses (Figure 1D, Figure S2A). Interestingly, the systemic T cell tone was shifted towards an inflammatory TH2 profile during the acute phase of the infection, as suggested by 228 229 increased IL-5, IL-6, TNFa, and IL-17 secretion following TCR cross-linking in COVID-19 230 patients compared with individuals without COVID-19 (Figure 1D, Figure S1C).

231 We next examined the polarization of SARS-CoV-2-specific memory T cell responses 232 between May and September 2020 in 54 convalescent COVID-19 individuals (median time 233 lapse between PCR negative and T cell assay: 85 days, range: 13-106 days) compared with 234 contemporary controls (Figure 1A, Figure 1C, Figure 1D, Figure S2, Table S2). A dominant 235 SARS-CoV-2-specific memory TH1 response (resulting in the secretion of IFNy, IL-2 and 236 $TNF\alpha$) prevailed in most convalescent subjects within the next 2-3 months after acute infection 237 (Figure 1D). Of note, SARS-CoV-2 specific IL-2 release at recovery correlated with an increase 238 in the frequency of circulating non-activated TFH cells (Figure S1D). In addition, SARS-CoV-2 specific IL-2 secretion was the only parameter correlating with anti-SARS-CoV-2 239

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

nucleocapsid (NC) antibody titers (reported to be stable for 8 months [5]) but not with IgG and
IgA antibodies targeting the S1 domain of the SARS-CoV-2 spike protein including the RBD
(Figure 1E-F and not shown).

243 More than 30% convalescent COVID-19 individuals displayed polyfunctional T cell 244 responses defined by at least 2 cytokines with a secretion ratio >1.5 (Figure S2A-B). Memory 245 TH1 (IL-2, IFNy) responses were comparable in both healthy and cancer subsets of COVID-19 246 positive individuals (Figure S2B-C). As previously described [21, 23, 24, 31, 32], contemporary 247 COVID-19 negative subjects also harbored significant SARS-CoV-2 specific-TH1/TC1 248 memory responses that appear to pre-exist in cancer patients and healthy individuals whose 249 blood was drawn in the pre-COVID-19 era, including prior to outbreaks of SARS-CoV-1 and 250 MERS (Figure S2B-C). The unsupervised hierarchical clustering considering 12 cytokines monitored in 358 subjects did not segregate pre-COVID-19 from contemporary unexposed 251 252 individuals nor convalescent patients (Figure S2A).

Hence, while polyfunctional T cell responses dominated by IL-2 and IL-5 were elicited during the acute phase of COVID-19, after convalescence, recirculating memory T cells exhibited a TH1/TC1 profile in about 70% of COVID-19 patients, correlating with anti-SARS-CoV-2 NC antibody titers.

257

258 Clinical relevance of the IL-2/IL-5 ratio to predict COVID-19 infection

259

260 We next determined the clinical significance of these memory T cell responses monitored in 261 unexposed individuals during the first surge of COVID-19 (mid-March to mid-May 2020) to 262 decipher the nature of memory T cells contributing to susceptibility or resistance to the 263 successive surges of this viral pandemic in fall 2020 and winter 2021. We phoned 229 patients to discover that 22 individuals had developed COVID-19 infections (diagnosed by qPCR or 264 265 serology) with different degrees of severity according to WHO criteria (Table S1, Figure 2A, 266 Table S4). Indeed, about one third of the initially COVID-19-free individuals became contact 267 cases (n=70) and 29% among these contact cases were diagnosed with COVID-19 infection by 268 specific RT-qPCR or serology (n= 22, Figure 2B, Table S4). The unsupervised hierarchical 269 clustering of the T cell secretory profiles in these 70 individuals failed to correctly segregate 270 resistant (contact) from susceptible (infected) cases (Figure S3A). In addition, the 271 polyfunctionality of T cell responses failed to segregate the two categories of individuals (Figure 2C, Figure S4B). However, two lymphokines, IL-2 and IL-5, secreted by memory T 272 273 cells responding to SARS-CoV-2 correlated with resistance and susceptibility to SARS-CoV-

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

2, respectively (Figure 2D-E). Indeed, the levels of IL-2 in the recall response and the 274 275 proportions of individuals exhibiting IL-2 polarized T cell memory responses were both 276 associated with resistance to COVID-19 (Figure 2D, p=0.01, two-sided Wilcoxon-Mann-277 Whitney test, Figure 2E, p=0.049, Fisher exact test). In contrast, IL-5 levels in recall responses 278 were associated with increased susceptibility to COVID-19 (Figure 2D, p=0.057, two-sided 279 Wilcoxon-Mann-Whitney test). Resistant individuals harbored a coordinated SARS-CoV-2 280 specific-TH1 response (IFNy, TNF α) in mid-March to mid-May 2020, while subjects 281 susceptible to COVID-19 exhibited inflammatory TH9/TH17-like networks (Figure S4C-D). 282 These findings are reminiscent of data segregating asymptomatic or mild from severe diseases [33, 34]. For this reason, we henceforth analyzed the clinical significance of the ratio between 283 284 SARS-CoV2-specific IL-2 and IL-5 release. Indeed, the IL-2/IL-5 recall response ratio was 285 significantly higher in cancer patients who were SARS-CoV-2-resistant (Figure 2F) and in 286 convalescent patients (Figure S4A). The vast majority (16 out of 19) of cancer patients doomed 287 to be infected with SARS-CoV-2 harbored an IL-2/IL-5 ratio <1, with the two severe COVID-288 19 cases exhibiting an IL-2/IL-5 ratio <10 (Figure S4B). In contrast, CCC-specific T cell 289 reactivities did not allow to discriminate susceptible from resistant individuals (Figure 2G), 290 although IL-5 stood out as the strongest correlate between SARS-CoV-2 and CCC-specific T 291 cell responses among 156 individuals with no correlation between SARS-CoV-2 and OC43-292 specific IL-2 secretion (Figure 2H). Reinforcing this notion, titers of IgG antibodies directed against the spike of the seasonal betacoronaviruses OC43 and HKU1 (but not the 293 294 alphacoronavirus 229E and NL63) were higher in individuals susceptible to SARS-CoV2 295 compared to resistant individuals (Figure 2I and not shown).

The SARS-CoV2-specific IL-2/IL-5 recall response ratio was also clinically significant in the cohort of cancer-free individuals that were locked down together with their COVID-19positive family members (Figure 2A, Table S3, Figure S4D). Individuals who did not get infected harbored IL-2/IL-5 ratios>1 reaching mean values comparable to those achieved in convalescent individuals (Figure 2F, Figure S4A) at higher frequencies than the overall population (Figure S4C).

We next compared the immunogenicity of the lysates derived from the original SARS-CoV-2 strain (IHUMI846) with that of the Danish (IHUMI2096, 20A.EU2, B.1.367, GH) and North African (IHUMI2514, 20C, B.1.160, GH) strains isolated at the end of 2020 [35]. Of note, T cells lost their capacity to produce IL-2 in response to the IHUMI2096 and IHUMI2514 viral variants while IL-17 release tended to increase (p= 0.0857, Figure S5A).

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

307 Given that 15-20% of convalescent individuals mounted a TH2/TC2 memory response 308 to SARS-CoV-2 (Figure S2A), we wondered whether these individuals could be at higher risk 309 to get re-infected by SARS-CoV-2 variants. Hence, we analyzed PBMCs in a series of 310 individuals (n=12) who were diagnosed with COVID-19 during the first surge of the SARS-311 CoV-2 pandemic and then were re-infected with a viral variant prevailing during the later 312 outbreak occurring in fall 2020 or winter 2021, comparing them to health care workers who 313 were multi-exposed cases with multiple negative oropharyngeal SARS-CoV-2 -specific PCR 314 assays (n=17) (Table S5, Figure 2J, left panel). Surprisingly, monocytes could be differentiated 315 into dendritic cells only in 4 re-infected patients. Unstimulated PBL from re-infected and re-316 convalescent subjects spontaneously secreted much higher levels of IL-5 than did PBL from 317 multi-exposed cases, reaching similar ranges as those obtained after TCR crosslinking (Figure 318 2J, middle panel). After specific re-stimulation with SARS-CoV-2 lysates, IL-10 was markedly increased in recall responses from re-infected but not multi-exposed cases (Figure 2J, right 319 320 panel) and IL-2 was undetectable (Figure S5B). In this small cohort of multi-exposed 321 individuals, the recognition pattern of the United Kingdom (UK) (IHUMI3076, B.1.1.7), South 322 Africa (IHUMI3147, B.1.351) and Brazil (IHUMI3191, P.1) [35] strains were quite variable, 323 some individuals losing the TH1/TC1 or acquiring a TH2/TC2 profile, depending on the strain 324 (Figure S5C).

We conclude that the TH1/TC1 *versus* TH2/TC2 polarity of SARS-CoV-2 specificmemory T cell responses is associated with effective clinical protection against infection, an IL-2/IL-5 ratio >1 indicating resistance to the COVID-19.

- 328
- 329

330 Defects in the TH1/TC1 response against the SARS-CoV-2 RBD of spike glycoprotein in 331 susceptible individuals

332

In hosts affected by viral infections or cancer, the breadth of T cell epitope recognition is a 333 334 prerequisite for protective immunity [36-38]. We analyzed the diversity of SARS-CoV-2 T cell 335 responses by single peptide mapping using 186 peptides with 9 to 51 amino acids corresponding 336 to 146 non-overlapping or poorly overlapping epitopes of the SARS-CoV-2 ORFeome (among 337 which 25 epitopes were shared with SARS-CoV-1), encompassing membrane, nucleocapsid, 338 spike, ORF3a, ORF8 and ORF10 proteins, plus 41 epitopes covering the SARS-CoV-1 339 ORFeome of immunological relevance (among which 8 epitopes were shared with SARS-CoV-340 2), as well as a series of positive controls, namely epitopes from Influenza virus, Epstein Barr

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

341 virus (EBV), Cytomegalovirus (CMV), phytohemagglutinin (PHA), and anti-CD3ε (OKT3) antibody. IFNy responses against these 186 peptides were evaluated in 164 individuals (123 342 343 unexposed individuals, 25 convalescent COVID-19-positive patients, 16 re-infected patients, see Table S6). To enable the detection of low-frequency SARS-CoV-2 peptide-specific T cells. 344 345 we used an in vitro 7 day-long, IL-2+IL-15 enriched IVS assay in the presence of each individual peptide in duplicates (Figure 3A). We chose to monitor IFNy, a proxy for TH1/TC1 346 347 responses, as opposed to IL-2, in the 7 day- coculture supernatants by ELISA because recombinant human IL-2 was already added to the IVS assay (Figure 3A). The overall 348 349 recognition patterns of these peptides across various patient populations, and their individual 350 frequencies are detailed in Figure 3B, and Figure S6-S7. About 10% convalescent individuals 351 recognized more than 15% of our peptide selection within the SARS-CoV-2 ORFeome (Figure 352 S6 inset). T cell responses in unexposed patients, in particular in the pre-COVID-19 era, 353 covered large specificities, as suggested by previous reports [9, 21, 24] (Figure 3C, right panel 354 and Figure S6). In accord with the literature [9, 24], the immune response of convalescent 355 COVID-19 patients was mainly directed against spike, membrane, and nucleocapsid (NC) and, 356 to a lower extent, against ORF3a, ORF8, and ORF10 (Figure 3B, 3D left panel). The breadth 357 of the peptide recognition coverage was not significantly reduced in cancer patients compared 358 with others (Figure 3B, 3C left panel). In a limited number of individuals, we measured not 359 only IFNy but also IL-5, IL-9 and IL-17 by ELISA. The recognition profile specific to the spike 360 (and more specifically the RBD) as well as ORF8 was more geared toward TH1/TC1 (IFNy) 361 than TH9 or TH2 (IL-9 or IL-5 production respectively) (Figure S8A-C). The membrane- and 362 NC-specific repertoire was strongly TH17 oriented (Figure S8B).

363

364 Using logistic regression analyses, we determined the TH1/TC1 peptide recognition fingerprint significantly associated with each patient category (Figure S9). The hallmark 365 366 repertoire of the pre-COVID-19 era consisted in a stretch of peptides covering part of the 367 SARS-CoV-1 genome (spike, membrane, ORF3a, NC), some peptide residues sharing high or 368 complete homology with SARS-CoV-2, as well as numerous ORF8 sequences (Table S6). Of 369 note, the recognition pattern of these SARS-CoV-1 epitopes highly correlated with responses 370 directed against ORF8 peptides (not shown). In contrast, the COVID-19-associated blueprint encompassed many nucleocapsid peptides (NC 1 (residues 1-15), NC 6-7 (residues 76-105, 371 372 NC 8 (residues 106-120) sharing 93% and 100% homology with OC43 and HKU1, respectively, the HLA-A2- restricted nonamer (RLNQLESKV) NC 226-234 from SARS-373

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

CoV-1 (sharing high structural homology with the SARS-CoV2 epitope RLNQLESK<u>M</u>) and
another SARS-CoV-1 NC nonamer peptide (NC_345-361), three peptides residing in ORF8,
two epitopes belonging to the RBD region ("SPIKE29") found at high frequency across subjects
(23.5%), as well as a peptide from the C terminal portion of spike ("SPIKE84", residues 12461260) (Figure S9A). Cancer patients tended to lack some specificities, yet with no prototypical
signature (Figure S9A).

380 Next, we investigated the ORFeome peptide repertoire associated with SARS-CoV-2-381 specific IL-2 memory responses in 118 unexposed individuals by means of linear regression 382 analysis (Figure 4A, left panel). Among the 9 peptides associated with a positive contribution 383 to IL-2 secretion, one nonamer (KLPDDFMGCV in SARS-CoV-1 genome and 384 KLPDDFTGCV in the SARS-CoV-2 genome) resided in the RBD region that constitutes the 385 binding site for its cellular receptor angiotensin-converting enzyme 2 (ACE2) [39] while, 386 conversely among the 13 peptides associated with a hole in the TH1 response, 5 resided within 387 the RBD of the spike glycoprotein. More specifically, there was a statistically significant 388 enrichment of RBD-related peptides within this TH1/TC1 hole (Figure 4A, right panel).

389 In order to validate the clinical significance of the TH1/TC1 repertoire hole and the 390 assumption that a defect in the TH1/TC1 recognition pattern of the RBD sequence could be a 391 risk factor for COVID-19, we calculated the number of positive peptides selected from the RBD 392 region spanning aminoacid 331-525 residues (called "SPIKE23" to "SPIKE35" in Table S6), in 393 each of the 83 individuals who were comprehensively explored in the peptide-based IVS assay, 394 37 resistant (contact) individuals, 14 infected persons (susceptible) as well as 32 controls 395 (unexposed lockdown and/or unknown) using the IFNy ELISA (Table S1). While susceptible 396 individuals exhibited a significant defect in the RBD-related TH1/TC1 repertoire (Figure 4B), 397 up to 25% of the resistant individuals harbored robust TH1/TC1 responses to the 331-525 398 aminoacid residues of RBD (Figure 4B, p=0.049, Fisher exact test). Again, the RBD-specific 399 TH1/TC1 responses were almost undetectable in patients who got infected twice with SARS-400 CoV-2 (Table S5), while they could be measured in 50% convalescent COVID-19 patients 401 (Figure 4C, p=0.011, Fisher exact test) in accordance with a recent report highlighting the 402 immunodominance of the S346-365 region (corresponding to our "SPIKE24" epitope) in 403 convalescent individuals [40]. Such S1-RBD-specific TH1 responses pre-existed in the pre-404 COVID-19 era at the same frequency in cancer or cancer-free individuals (Figure 4D). T cell 405 responses directed against S1-RBD peptides were evaluated for both IL-5 and IFNy secretions 406 in 36 patients. They almost exclusively exhibited a TH1 pattern (in 10/36 cases), with only 3/36 407 individuals harboring a TH2 profile (Table S7). Of note, there was a robust consistency and

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

408 concordance of the polarization status of patients between the two (cross-priming and peptide-409 based) IVS assays (McNemar test, p= p.val=2,2e-16 comparing SARS-CoV-2 or peptide-410 specific IL-2 and IFNy release, McNemar test, p= p.val=2.2e-16 comparing SARS-CoV-2 or 411 peptide-specific IFNy release, p.val <1e-16).

We performed immunoinformatic-based prediction analyses of S1-RBD peptide 412 413 binding affinities to MHC class I and class II molecules using the NetMHCpan algorithm. This 414 approach revealed strong binding affinities to MHC class I HLA-A, -B and -C alleles for the RBD epitopes "SPIKE25" (residues 361 375), "SPIKE27" (residues 391-405), "SPIKE31" 415 416 (residues 451-465). In contrast, "SPIKE33" (residues 481 495) was predicted to have a low or 417 absent affinity for HLA-B and HLA-C alleles, respectively (Table S8a). Only "SPIKE24", 418 "SPIKE25" and "SPIKE31 were predicted to bind with a high affinity to HLA-DR alleles (Table 419 S8b) as already reported for the immunodominant S346-365 region [40].

In accordance with the immunodominance of S1-RBD, the other signatures indicated
by our logistic regression analysis (Figure S9A), namely the convalescent or the pre-COVID19 era -related blueprints were not significantly associated with COVID-19 resistance (Figure
S9B-C).

Given that immunoselection may drive antigenic drift of viruses as well as the evolution of viral phylogeny, we analyzed the coincidence of hot spot mutations in the SARS-CoV-2 ORFeome [41] with T cell memory patterns of clinical significance (Table S9). Of note, significantly higher mutation frequencies were detected within the S1-RBD-specific TH1 response (62%) compared with other regions of the SARS-CoV2 orfeome (26%) (Odd Ratio = 0.21, 95% confidence interval [0.06; 0.68], p=0.01, Figure 4E).

430 During the course of this study, two SARS-CoV-2 mRNA vaccines were approved by 431 FDA and EMA based on reports that they prevent COVID-19 infection with an efficacy of 432 >90% [3]. Using a simple whole blood stimulation assay allowing the detection of IFNyproducing anti-viral T cells following peptide stimulation within 18 hours [42], we analyzed 433 434 RBD-specific T cell reactivities before and after dual vaccination with BNT162b2 mRNA (BioNTech/Pfizer) in 70 unexposed health care workers (HCW) and 14 COVID-19 435 convalescent HCW (Table S10). The vast majority (approximately 90%) of naive vaccinees 436 437 mounted robust RBD-specific TH1/TC1 cell responses after 2 immunizations (Figure 4F).

Hence, our findings suggest that defects in the TH1 repertoire affecting the recognition
of SARS-CoV-2 S1-RBD are associated with susceptibility to infection or re-infection by

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

440 SARS-CoV-2. This antigenic region appears to mutate more than other regions of the SARS-

441 CoV-2 orfeome, perhaps as a result of an immune system-mediated evolutionary pressure.

442

443

444 **Discussion**

445

446 Here, we unravel the first *prospective* correlation between preexisting (before the first 447 surge) SARS-CoV-2-specific TH2/TC2 immune responses and susceptibility to infection with 448 SARS-CoV-2 or re-infection with viral variants. Both in cancer patients and cancer-free 449 subjects, the best immunological correlate with future SARS-CoV-2 infection was 450 undistinguishably a recall response characterized by a low ratio of TH1/TH2 lymphokines (and 451 more precisely an IL-2/IL-5 ratio <1) secreted upon exposure to the original SARS-CoV-2 viral 452 strain. This recall response coincided with a hole within the TH1/TC1 cell repertoire affecting 453 the RBD of the spike protein. Moreover, in a small series of re-infected individuals, maladaptive 454 anti-SARS-CoV-2 responses were characterized by elevated baseline TH2 responses 455 (spontaneous IL-5 release from PBL) and IL-10-centered recall responses. Finally, vaccinees 456 immunized with a clinically approved mRNA encoding the spike protein mounted a robust 457 RBD-specific TH1/TC1 response, that may account for immune protection.

458 Reportedly, CD4⁺ TH1 and TH2 responses are induced during the primary phase of 459 viral infection, and both TH1 and TH2 can generate an anamnestic response upon rechallenge 460 with the same virus [43]. Survivors from SARS-CoV-1 infection developed polyfunctional T 461 cells producing TH1 cytokines and long-term CD8⁺ T cell responses as late as 11 years post-462 infection [9]. The TH1 cytokine IL-2 (which correlated with circulating non-activated TFH 463 cells in convalescent patients in our study) was the pivotal factor allowing us to distinguish 464 susceptible from resistant individuals. Signaling via the high-affinity IL-2 receptor (which requires CD25/IL-2Ra expression) favors the generation of CXCR5⁻ T effector cells, and this 465 466 is associated with TH1 responses sustained by the transcription factor TBX21. Moreover, the 467 development of IFNy producing effector memory T cells depends upon CD25 [15]. 468 Accordingly, upon infection with lymphocytic choriomeningitis (LCMV), CD25-deficient 469 CD4⁺ T cells largely fail to form IFNy producing T effector cells in secondary lymphoid organs 470 and to generate lung tissue resident memory T cells [44].

In contrast, increased TH2 cytokine release correlated with poor outcome in patients, a
finding corroborated in mouse studies of SARS-CoV-1 [45, 46]. During SARS-CoV-2
infection, TH2-associated blood markers, such as eosinophilia and circulating IL-5, IL-33,

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

474 eotaxin-2 and eotaxin- 3 correlated with COVID-19 severity, contrasting with the fact that 475 $CD4^+$ and $CD8^+$ T cells from COVID-19 patients secrete comparable amounts of IFN γ in 476 moderate and severe disease [47].

477 What cellular cues may influence TH2 differentiation or maintenance? Distinct 478 dendritic cell subsets could specifically induce TH2 immunity, while limiting TFH responses 479 and humoral immunity [48-50]. Indeed, preferential trans-vasation of blood-born cDC2 (CD1c⁺ 480 DC) into the bronchoalveolar fluid was described for severe COVID-19 [51], and TH1/TH2 481 polarization is not only achieved during the priming response in lymphoid organs but is largely 482 driven by the preferential expansion of either TH1 or TH2 cells in non-lymphoid tissues [52]. 483 Various cell types located in peripheral tissues can impact T cell fate [53]. In the lungs of severe 484 COVID-19 patients, a clonal expansion of IL-17A/F and GM-CSF producing TRM-like CD4⁺ 485 T cells persisted even after viral clearance [34]. Our findings point to some correlative links 486 between IL-5 and GM-CSF in recall responses from individuals susceptible to COVID-19. 487 While IL-7 secreting stromal cells may promote survival of TH2 memory cells within lung 488 tertiary lymphoid structures [54, 55], it remains unclear to which extent local (oropharyngeal 489 or pulmonary) cues might influence the maintenance of SARS-CoV-2 specific or cross-reactive 490 TH2 responses.

491 TCR signaling plays a major role in CD4⁺ polarization and can vary according to the 492 TCR affinity, the amount of peptide/MHC-II complexes perceived by a TCR, or the length of 493 time a T cell spends proofreading peptide/MHC-II complexes [15]. Of note, the RBD-specific TH1/TC1 responses against regions 361 375 and 391 405 of spike exhibited robust binding 494 495 capacities across all MHC class I alleles. Several authors reported cross-reactivities between 496 CCC and SARS-CoV2 [9, 20, 23, 24, 31, 32, 56, 57]. However, such cross-reactive T cells may 497 turn out to be harmful with respect to clinical correlations [58-63]. Indeed, according to one 498 report [21]. preexisting CCC-specific memory CD4⁺ T cells exhibit low TCR avidity in almost 499 all unexposed individuals, and are strongly expanded in severe COVID-19 but not in mild cases. 500 Moreover, CCC/SARS-CoV-2-cross-reactive T cell clones shared among convalescent and 501 infected individuals harbored lower functional avidity than non-cross-reactive clones, suggesting antigenic imprinting of the TCR repertoire by previous exposure to CCC [25, 82]. 502 503 Of note, these spike-specific cross-reactive CD4⁺ T cells might not only re-expand during 504 infection but also following vaccination. In line with this possibility, we detected a strong 505 positive correlation between CCC and SARS-CoV2-specific IL-5 release by memory T cells in 506 all unexposed individuals. Moreover, CCC-specific IgG titers were higher in susceptible 507 compared to resistant individuals. Finally, the SARS-CoV-1 and ORF8-specific T cell

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

repertoire prevailing in the pre-COVID-19 era failed to be clinically relevant for the avoidance of COVID-19 and such a repertoire was frequently detected in re-infected individuals during their convalescence phase. Hence, we cannot rule out the possibility that a preexisting TH2 immunity, for instance directed against sequences shared by sarbecoviruses [9] could increase the susceptibility to, and severity of, SARS-CoV-2 infection [45-47].

513

514 The landscape of prevalence and immunodominance of SARS-CoV-2 epitopes - supposedly 515 associated with protection during the acute phase - has been thoroughly investigated [64]. Using 516 40-mer peptide pools covering regions of membrane, nucleocapsid, ORF3a, ORF7/8, and spike proteins. Tan et al. observed a statistically significant correlation between the early appearance 517 518 of SARS-CoV-2 peptide-reactive cells and shorter duration of infection [65]. However, viruses 519 employ numerous strategies to evade CD8⁺ T cell immune responses [66]. Our data obtained in COVID-19-free individuals who remained resistant to overt infection despite exposure to the 520 virus strongly support the immunological and clinical relevance of memory TH1/TC1 521 522 responses directed against the spike S1-RBD region. An immune-driven selection process of 523 viral phylogeny can occur [67]. Early (but transient) induction of ORF7/8-specific TH1 cell 524 immune responses as well as antibody responses against ORF8 have already been reported 525 during the acute phase of COVID-19 in small numbers of patients. Some arguments plead for 526 the biological significance of ORF8-specific T cell immunity in viral control. Indeed, a 382nucleotide deletion that truncates ORF7b and ORF8, culminating in the loss of ORF8 527 528 transcription, and conferring mild forms of infections [68] has been reported [69]. However, 529 our data do not support the clinical relevance of ORF8-specific immune responses.

530 There is growing evidence of the links between mutations within the SARS-CoV-2 531 spike protein and the evasion of neutralizing antibody responses [70, 71]. Single 532 nonsynonymous mutations in SARS-CoV-2 can theoretically subvert the immune response to 533 CTL epitopes as well [72]. These studies suggested that immune selection may shape the mutational landscape of CD8⁺ T cell epitopes. Our data fuel the theory that i) robust TH1 534 535 memory immune responses against RBD might be important in restraining viral infection, thus exerting a selective pressure on the virus, obliging it to generate escape variants by mutation of 536 RBD, ii) preexisting TH2 antiviral responses might not only be incapable of eliminating SARS-537 CoV-2-infected cells but actually favor (re-)infection with SARS-CoV-2, ultimately increasing 538 539 the viral reservoir, thus favoring the emergence of viral variants.

540

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

Our work may have important consequences for the design of next-generation vaccines 541 542 against COVID-19. Immunization strategies should aim at triggering SARS-CoV-2 specific 543 TH1/TC1 (rather than TH2/TC2) responses. The efficacy of cellular immune response relies on 544 three components, (i) the antigen, (ii) the adjuvant and (iii) the dynamics of viral evolution [73]. Immunization with inactivated SARS-CoV-1 or with the whole spike (S) protein, caused 545 546 eosinophilic infiltration following viral re-exposure in mice [74, 75]. In contrast, at least in the 547 case of SARS-CoV-1, immunization with RBD induced neutralizing antibodies in the absence 548 of a TH2/TC2 response [76]. Vaccine adjuvants can stimulate TH1/TC1-favorable innate 549 immunity [77, 82], as this is the case for multiple viral vectors, virus-like particles and mRNA 550 containing nanoparticles. Finally, virus adaptation to the host has to be outcompeted. One might infer from our data that the currently protective immunodominant regions generating a 551 TH1/TC1 profile may be the focus of the future antigenic drift of SARS-CoV-2. 552

Community-protective immunity can affect RNA virus evolution by selecting for new 553 antigenic variants on the scale of years, as exemplified by the need for annual evaluation of 554 555 influenza vaccines [78]. It is likely that pandemic SARS-CoV-2 evolution bears similarities 556 with human influenza A virus evolution including accumulation of adaptive changes in the receptor binding domain (RBD), in which case vaccines would have to be updated regularly 557 558 [78]. Therefore, to win the race against current virus strains and emerging variants, an expedited 559 world-wide vaccination rollout ensuring an immunization en masse against relevant epitopes (and in particular the entire RBD region of the variants from Brazil, India, and South Africa) 560 561 with vaccine formulations ensuring TH1/TC1 (rather than TH2/TC2) responses should outwit 562 the COVID-19 pandemic. It will be of utmost interest to monitor the polarity and specificity 563 elicited by current COVID-19 vaccines and to correlate these recognition profiles with failed 564 immunization, reinfection and emergence of severe disease.

- 565
- 566

567 SUPPLEMENTAL MATERIALS

568

569 Material and methods

570 Patient and cohort characteristics. All clinical studies were conducted after written informed 571 consent in accordance with Good Clinical Practice guidelines and the provisions of the 572 Declaration of Helsinki. Cohorts' characteristics are detailed in Table S1, Figure 1A and Figure 573 S1. Two cohorts of cancer patients (from the pre-COVID-19 era and from the COVID-19 era) 574 and three cohorts of healthy volunteers (from the pre-COVID-19 era and from the COVID-19 575 period including a cohort of vaccinees) were exploited to set up the translational research 576 analyses. Peripheral blood mononuclear cells (PBMC) were provided by Gustave Roussy

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

17

577 Cancer Campus (Villejuif, France) and IHU Méditerranée Infection (Marseille, France) (see578 Blood analyses section).

579

580 Contemporary clinical studies (COVID-19 era): 1/ ONCOVID clinical trial and regulatory
 581 approvals.

582 Principles. The protocol is available at https://clinicaltrials.gov/ct2/show/NCT04341207. 583 Gustave Roussy Cancer Center sponsored the trial named `ONCOVID` and collaborated with 584 the academic authors on the trial design and on the collection, analysis, and interpretation of 585 the data. Sanofi provided trial drugs. Protocol approval was obtained from an independent 586 ethics committee (ethics protocol number EudraCT No: 2020-001250-21). Patients. 587 ONCOVID eligible patients were all comer adults with advanced solid tumors or advanced 588 hematological malignancies spontaneously presenting at Gustave Roussy between April 10th, 2020 and January 15th, 2021 (data cut-off for our analyses). *Trial design*. Cancer patients were 589 590 screened for SARS-CoV-2 virus carriage by nasopharyngeal sampling at every hospital visit. 591 The presence of SARS-CoV-2 RNA was detected by RT-qPCR assay in a BSL-2 laboratory. 592 Asymptomatic and symptomatic patients (*i.e* presenting with fever (t°>38°C) and/or cough 593 and/or shortness of breath and/or headache and/or fatigue and/or runny nose and/or sore throat, 594 anosmia/ageusia) with a positive SARS-CoV-2 RT-qPCR test, shifted to the interventional 595 phase (tailored experimental approach with Hydroxychloroguine and Azithromycin therapy in 596 symptomatic SARS-CoV-2 positive subjects). Asymptomatic or symptomatic patients with 597 negative SARS-CoV-2 RT-qPCR tests continued their standard of care anti-cancer treatments. 598 Repeated RT-qPCR for SARS-CoV-2 on nasopharyngeal swabs and blood samples were 599 performed to monitor the status for SARS-CoV-2 and the immune response, respectively, in 600 COVID-19 positive and negative patients. The COVID-19 severity was defined based on oxygen, imaging and hospitalization criteria (WHO criteria). Unexposed and exposed 601 602 individuals included in the ONCOVID trial during the first surge were followed-up by 603 telephone interview at 12-months in order to record documented COVID-19 infections and 604 degree of severity (WHO criteria) during the successive surges. Samples for translational 605 research. PMBCs were isolated less than 8 hours after the blood collection (at patient inclusion and at every hospital visit) and kept frozen at-80°C. 2/ PROTECT-Cov clinical trial and 606 607 regulatory approvals. Principles. IHU Méditerranée Infection sponsored the trial named 608 'PROTECT-Cov' and collaborated with the academic authors on the trial design and on the 609 collection, analysis, and interpretation of the data. Protocol approval was obtained from an independent ethics committee (ethics protocol number ANSM No: 2020-A01546-33). The trial 610 611 was conducted in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki. All patients provided written informed consent. Subjects. PROTECT-612 Cov eligible subjects were members of the same family/home composed of two or more people 613 614 and selected from the microbiology laboratory register on SARS-Cov-2 tests performed 615 between March 23 and April 10, 2020. Trial design. Members of the same family/home who 616 had at least one (a)symptomatic COVID-19 + case (RT-qPCR <35 Ct values for SARS-CoV-2 617 on nasopharyngeal swabs) and at least one member with negative RT-qPCR for SARS-CoV-2 618 (≥35 Ct) were screened. A telephone interview was conducted in order to confirm and complete 619 the list of family circles in connection with the positive case. The compliant subjects finally 620 selected were invited to come back to the IHU Méditerranée Infections hospital where they

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

were included in the trial and had a blood test. 3/ COVID-SER clinical trial and regulatory 621 approvals. Principles. At the "Hospices Civils de Lyon", France was conducted the trial named 622 623 COVID-SER. Protocol approval was obtained from an independent ethics committee (the 624 national review board for biomedical research. Comité de Protection des Personnes Sud 625 Méditerranée, ID-RCB-2020-A00932-37). The clinical study registered was on ClinicalTrial.gov (NCT04341142). Written informed consent was obtained from all 626 627 participants and the study. *Subjects. COVID-SER* eligible subjects were health care workers 628 who received the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2. All subjects with 629 a positive SARS-CoV-2 RT-PCR prior vaccination and/or a positive serological result with 630 Wantaï Ab total kit at the pre-vaccination visit were considered as convalescent. Blood sampling was performed before vaccination and 4 weeks after receiving 1 or 2 doses of vaccine 631 632 for naive and convalescent health care workers respectively. According to French procedures, 633 a written non-opposition to the use of donated blood for research purposes was obtained from healthy volunteers. The donors' personal data were anonymized before transfer to our research 634 635 laboratory. We obtained approval from the local ethical committee and the French ministry of 636 research (DC-2008-64) for handling and conservation of these samples. Human biological 637 samples and associated data were obtained from NeuroBioTec (CRB HCL, Lyon France, 638 Biobank BB-0033-00046) and Virginie Pitiot.

639

Clinical studies from the Pre-COVID-19 era: 1/ Series of patients with cancer: This cohort 640 641 is composed of different IGR clinical trials. Patients were included and blood was collected and 642 banked between 1999 and 2018 (Pre-COVID-19 era). Clinical studies: 1/ Patients with acute 643 myeloid leukemia admitted in the Hematology Department of IGR in Villejuif, France, between March 2008 and March 2009 were included. The study was approved by the local 644 645 ethics committee (Comité de Protection des Personnes (CPP) Hopital Bicêtre -CALEX 646 protocol, n1 ID RCB 2007-A01074-49, date 29 February 2008). The main clinical and biological characteristics of the patients are summarized in [30] PMBC were isolated less than 647 648 8 hours after the blood collection (before chemotherapy) and were kept frozen at -80°C. 2/ Phase II vaccine trial immunizing cancer patients (diagnosed with inoperable Non-small cell 649 650 lung cancer after induction with four cycles of platinum-based chemotherapy) with autologous 651 DC-derived exosomes and cyclophosphamide (CTX) (Study code « Dex2 »: NCT01159288, 652 date 19 December 2005) [28]. Eligible patients required at least stabilization of their disease 653 prior to being on maintenance immunotherapy with sc injections of IFNy- dendritic cell derived-exosomes loaded with MHC class I and class II-restricted cancer antigens. PBMCs 654 were collected at baseline after the 4th cycle of platinum-based chemotherapy, before 655 656 metronomic CTX followed by exosome injections and were kept frozen at -80°C. 3/ Phase I/II study of intradermal and subcutaneous immunization with the recombinant MAGE-3 protein in 657 658 patients with MAGE-3 positive, measurable non visceral metastatic melanoma. The study was 659 approved by the local ethics committee (Study code « LUD 99 003 »: N-CSET : 99/090/752, date 1 December 1999). Patients were required to have cutaneous melanoma with detectable 660 cutaneous and/or lymph node metastasis, but no visceral metastasis (AJCC 1997 stage III or 661 662 IVM1a). No chemotherapy, radiotherapy, or immunotherapy was allowed in the 4-week period 663 before the first vaccination. PBMCs were collected at baseline before the first vaccination and

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

were kept frozen at -80°C. 4/Adult patients with metastatic or locally advanced solid 664 malignancy, measurable or evaluable disease who were refractory to standard therapy were 665 666 eligible for the study (Phase I IMAIL-2 trial approved by the Kremlin Bicêtre Hospital Ethics 667 Committee [no 07–019] and the Agence Française de Sécurité Sanitaire des Produits de Santé [no A70385–27; EudraCT N°:2007–001699–35 in 2007) [79]. They received Imatinib mesylate 668 669 (IM) combined with increasing doses of IL-2. PMBCs were isolated less than 8 hours after the 670 blood collection (at baseline before treatment) and were kept frozen at -80C. 2/ Series of 671 patients without cancer : Peripheral blood was obtained from healthy volunteers at the 672 Etablissement Francais du Sang (EFS, Paris France, n 18EFS031 date 24 September 2018).

673 Blood analyses. Blood samples (for serum and PBL) were drawn from patients enrolled in the different cohorts presented in the cohort description section above. Whole human peripheral 674 675 blood was collected into sterile vacutainer tubes. Anti-SARS-CoV-2 immunoglobulins 676 *measurements*. Serum was collected from whole blood after centrifugation at 600 g for 10 min at room temperature and transferred to -80°C freezer to await analysis. Serological analysis 677 678 SARS-CoV-2 specific IgA, IgM and IgG antibodies were measured in 119 serum samples from 679 87 patients (Supplementary Material Figure 1) with The Maverick TM SARS-CoV-2 Multi-680 Antigen Serology Panel (Genalyte Inc. USA) according to the manufacturer's instructions. The 681 Maverick[™] SARS-CoV-2 Multi-Antigen Serology Panel (Genalyte Inc) is designed to detect antibodies to five SARS-CoV-2 antigens: nucleocapsid, Spike S1 RBD, Spike S1S2, Spike S2 682 683 and Spike S1 or seasonal HCoV -NL-63 nucleocapsid, -OC-43, -229E and -HK-U1 Spike in a multiplex format based on photonic ring resonance technology. This system detects and 684 measures with good reproducibility changes in resonance when antibodies bind to their 685 686 respective antigens in the chip. The instrument automates the assay. Briefly, 10µl of each serum 687 samples were added in a sample well plate array containing required diluents and buffers. The 688 plate and chip are loaded in the instrument. First the chip is equilibrated with the diluent buffer to get baseline resonance. Serum sample is then charged over the chip to bind specific 689 690 antibodies to antigens present on the chip. Next, chip is washed to remove low affinity binders. 691 Finally, specific antibodies of patients are detected with anti-IgG or -IgA or -IgM secondary 692 antibodies. Isolation of peripheral blood mononuclear cells (PBMCs) from fresh blood 693 sampling. Venous blood samples (10ml to 30ml) were collected in heparinized tubes (BD 694 Vacutainer® LH 170 U.I., Dutscher, UK). On the same day, blood was processed in a biosafety 695 level 2 laboratory at Gustave Roussy Institute, Villejuif, France, or in IHU Méditerranée 696 Infection, Marseille, France. Peripheral blood mononuclear cells (PBMCs) were freshly 697 isolated by LSM, Lymphocyte Separation Medium (Eurobio Scientific, France) density 698 gradient centrifugation according to manufacturer's instructions. (Leucosep tubes, Greiner; 699 Biocoll, Bio&SELL). PBMCs were then collected, washed once with phosphate-buffered saline solution (PBS) and aliquoted in 1ml of cryopreservation medium (CryoStor®, STEMCELLS 700 701 Technologies, USA) in cryovials (two cryovials per patient). Cryovials (CryotubeTMvials 702 ThermoFisher Scientific, Denmark) were conserved for 24h at -80°C in a cryo-freezing container (Mr.FrostyTM, Thermo Fisher Scientific) before storage in liquid nitrogen. 703

704 Viral studies. *Biosafety levels for in vitro experiments*. Frozen PBMCs from patients with a 705 confirmed negative RT-qPCR for SARS-CoV-2 genome at the time of blood drawing were 706 processed in a biosafety level 2 laboratory at Gustave Roussy Institute, Villejuif, France. All 707 samples from patients with positive RT-qPCR were processed in a biosafety level 3 laboratory

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

708 at Henri Mondor Hospital, Créteil, France. When a patient was sampled at different timepoints, 709 samples were processed together in the same laboratory. RT-qPCR analysis. SARS-CoV-2 710 diagnostic testing of clinical nasopharyngeal swabs or other samples by RT-qPCR was 711 conducted from 14 March to 23 March 2020 at an outside facility using the Charité protocol. 712 From the 23th March 2020 testing was performed internally at the Gustave Roussy. The cycle 713 thresholds were collected only for assays performed at Gustave Roussy. Nasopharyngeal swab 714 samples were collected using flocked swabs (Sigma Virocult) and placed in viral transport 715 media. SARS-CoV-2 RNA was detected using one of two available techniques at Gustave 716 Roussy: the GeneFinder COVID-19 Plus RealAmp kit (ELITech Group) targeting three regions 717 (*RdRp* gene, nucleocapsid and envelope genes) on the ELITe InGenius (ELITech Group) or the 718 multiplex real-time RT-PCR diagnostic kit (the Applied Biosystems TagPath COVID-19 CE-719 IVD RT-PCR Kit) targeting three regions (ORF1ab, nucleocapsid and spike genes) with the 720 following modifications. Nucleic acids were extracted from specimens using automated 721 Maxwell instruments following the manufacturer's instructions (Maxwell RSC simplyRNA 722 Blood Kit; AS1380; Promega). Real-time RT-PCR was performed on the QuantiStudio 5 Dx 723 Real-Time PCR System (Thermo Fisher Scientific) in a final reaction volume of 20 µl, 724 including 5 μ l of extracted nucleic acids according to the manufacturer instruction. Viral lysates 725 and their production. SARS-CoV-2 IHUMI2, IHUMI845, IHUMI846, IHUMI847 (early 2020) 726 episode), IHUMI2096 (20A.EU2, B.1.160) and IHUMI2514 (20C, B.1.367) [80] IHUMI3076 727 (20I/501Y.V1, B.1.1.7), IHUMI3147 (20H/501Y.V2, B.1.351) and IHUMI3191 728 (20J/501Y.V3, P.1) strains were isolated from human nasopharyngeal swab as previously 729 described [35] and grown in Vero E6 cells (ATCC CRL-1586) in Minimum Essential Medium 730 culture medium (MEM) with 4% fetal calf serum (FCS) and 1% L-glutamine. Influenza strains 731 H1N1 (0022641132) and H3N2 (8091056304) were isolated then produced from human 732 nasopharyngeal swab in MDCK cells (ATCC CCL-34) in MEM with 10% FCS and 1% Lglutamine. All these clinical isolates were characterized by whole viral genome sequencing 733 734 from culture supernatants. Coronavirus OC43 (ATCC vr-1558) was grown in HCT8 cells 735 (ATCC CCL-244) in RPMI with 10% FCS. Coronavirus 229E (ATCC vr-740) was grown in 736 MRC5 cells (ATCC CCL-171) in MEM with 10% FCS. All reagents for culture were from 737 ThermoFisher Scientific and all cultures were incubated at 37°C under 5% CO₂ without 738 antibiotics. All viral strains were produced in 125 cm² cell culture flasks. When destruction of cell monolayer reached approximately 80%, between 2 to 7 days according to cell line and viral 739 740 strain, culture supernatant was harvested. After low speed centrifugation to remove cells and 741 debris (700 x g for 10 min.) supernatants were filtered through 0.45 then 0.22 µm pore-sized 742 filters. These viral suspensions were then inactivated for 1 hour at 65°C before use. Batches of 743 scrapped control uninfected cells were rinsed twice in PBS, and then finally resuspended in 5 744 ml of PBS at 5.10⁵ cells/ml. All cells and antigens were tested negative for Mycoplasma before 745 use.

746 In vitro stimulation assays. Cross-presentation assay or peripheral blood lymphocyte

747 stimulation with autologous monocyte derived- dendritic cells (DC). Frozen PBMCs were 748 thawed, washed and resuspended in RPMI 1640 media (GIBCO). Viability and count were 749 evaluated using a Vi-Cell XR Cell Counter (Beckman Coulter, Brea). PBMC were then cultured in RPMI 1640 supplemented with 10% human AB serum, 1mM Glutamine, 1% sodium 750 751 pyruvate, 1% HEPES, 1% penicillin/streptomycin at a cell density of 0.5M cells/cm² for 2 hours 752 at 37°C, 5% CO₂ and separated into adherent and non-adherent cell populations. Non-adherent 753 cells, containing Peripheral Blood Lymphocytes (PBL), were collected and cultured 4 days at 754 37°C, 5% CO₂ in IMDM medium (Sigma-Aldrich, UK), supplemented with 10% human AB 755 Biotechnologies serum (Institut de Jacques Boy, France), 1mM Glutamine

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

756 (GIBCO/ThermoFisher Scientific, UK) 1% Sodium Pyruvate (GIBCO/ThermoFisher Scientific, HEPES (GIBCO/ThermoFisher Scientific, 757 UK). 1% UK). 1% 758 penicillin/streptomycin (GIBCO/ThermoFisher Scientific, UK) and 200 UI/mL rhIL-2 759 (Miltenyi, Germany). The adherent cell population was cultured for 3 days, at 37°C, 5% CO₂, 760 in a mo-DC differentiating media containing RPMI 1640 supplemented with 10% human AB serum, 1mM Glutamine, 1% sodium pyruvate, 1% HEPES, 1% penicillin /streptomycin, 761 762 1000UI/mL rhGM-CSF (Miltenvi) and 250UI/mL human IFNa-2b (Introna, MSD France). At day 3, adherent cells were slowly detached by pipetting after 20 minutes of incubation at 4°C 763 764 and 20.000 cells were seeded in 96 well round bottom plate and were pulsed, or not (control 765 condition), overnight, at 37°C, 5% CO₂, with 1/10 heat inactivated viral lysates, or their respective control (see viral lysates production section). Spinoculation (800g for 2h, Centrifuge 766 767 5810R, Eppendorf, Germany) was next performed to ensure synchronized capture of the viral 768 particles by mo-DCs. For activation and maturation, adherent cells were stimulated with LPS (10 ng/mL, Thermofisher) and GM-CSF (1000UI/mL). After 6h, mo-DCs were washed twice 769 770 to remove LPS from the media and 100 000 PBL/well were seeded onto mature mo-DCs. PBL 771 alone served as negative control, and PBL stimulated with anti-CD3 and anti-CD28 microbeads 772 (1µL/mL, Dynabeads T-Activator, InVitrogen) as a positive control. moDC-PBL co-culture was incubated at 37°C, 5% CO₂ for 48h and supernatants were harvested and stored at -20°C. 773

774 Multiplex Cytokine Analysis or bead-based multiplex assays. moDC-PBL co-culture 775 supernatants were analyzed using bead-based multiplex kit assays (MACSplex cytokine 12 human, Miltenyi) according to the manufacturer protocol. Briefly, 50uL of supernatant were 776 777 used with a MACSPLEX Cytokine12 Capture Beads (Miltenyi, France) to measure the 778 concentration of 12 cytokines (GM-CSF, IFN-a, IFN-y, IL-10, IL-12, IL-17A, IL-2, IL-4, IL-779 5, IL-6, IL-9, TNF-a). Bead fluorescence was acquired on a CytoFLEX flow cytometer 780 (Beckman Coulter) for samples processed at Gustave Roussy Institute and on a FACSAria 781 Fusion (Becton Dickinson) for samples processed in the biosafety level 3 laboratory at Henri 782 Mondor Hospital. FlowJo (Treestar, Ashland, OR, USA) software was used for analysis.

783 **Peptide-based assay.** Lyophilized peptides were dissolved in sterile water and used at 2µg/mL 784 in RPMI 1640 glutamax media (GIBCO) supplemented with 1% penicillin/streptomycin (GIBCO). 185 single peptides were plated in duplicates in 96 well round bottom TPP treated 785 786 culture plates. Peptide plates were then stored at -80°C until use. The day of the experiment, 787 peptide plates were thawed at room temperature. Frozen PBMCs were thawed, washed and resuspended in RPMI 1640 media (GIBCO). Viability and count were evaluated using a Vi-788 789 Cell XR Cell Counter (Beckman Coulter, Brea). PBMCs were then plated in RPMI 1640 790 glutamax media (GIBCO) supplemented with 1% penicillin/streptomycin (GIBCO), with 791 200UI/mL rhIL-2 (Miltenyi) and 200UI/mL rhIL-15 (Miltenyi) at a cell density of 10x10³ cells 792 and incubated with each peptide at 37°C, 5% CO₂. PBMCs were stimulated with 60 ng/mL 793 OKT-3 antibody (ThermoFisher Scientific, clone OKT3) or with 10µg/mL phytohemagglutinin 794 as positive controls and PBMCs alone served as negative controls. After 6 hours, 20µL of 795 human AB serum was added to each well and plates were incubated at 37°C, 5% CO₂ for 6 796 additional days. On day 7, supernatants were harvested and frozen at -80°C. Concentration of

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

797 IFNγ, IL-9, IL-5 and IL-17A in the culture supernatant was determined using a commercial
 798 ELISA kit (ELISA Max Deluxe set human IFN-γ, Biolegend).

799 Positivity threshold determination for cytokine concentration using multiplex assays and

commercial ELISA assays. For multiplex assays (or ELISA), a 4 parameter logistic regression 800 801 was fitted for each cytokine based on the APC mean fluorescent intensity(or Optical Density) 802 of standard dilution samples using nlpr(v0.1-7). This model was then used to calculate the 803 concentration of each sample of unknown concentration. For multiplex assays, a ratio was 804 computed for each cytokine using the cytokine concentration measured in response to each 805 virus (SARS-CoV-2, HCoV-229E, HCoV-OC43) divided by the median concentration of their 806 respective biological controls (Vero 81, MRC5, HCT8). A positivity threshold was set up based 807 on the ratio for each cytokine. A ratio of above 1.5 minimum was requested to consider the 808 supernatant "positive" for a cytokine. When necessary, a higher threshold was set up as such, 809 median cytokine concentration of the biological controls + 2 times the standard deviation of the biological control concentrations divided by the median concentration. For ELISA assays, 810 811 a ratio was computed as the concentration of the sample divided by the mean concentration of

the negative controls.

813 COVID IGRA Biomérieux assay utilized for the COVID-SER clinical trial vaccinees [42]. Fresh blood collected in heparanized tubes was stimulated for 22 hours at 37°C under 5% of 814 815 CO2 with peptide pools targeting RBD (46 peptides) (bioMérieux,France) diluted in IFA 816 solution (bioMérieux, France). The IFA solution was used as a negative control and a mitogen 817 was used as a positive control. The peptides (15-mer) encompassed the whole RBD protein 818 sequence and overlapped by 5-residues. The concentration of IFN γ in the supernatant was 819 measured using the VIDAS automated platform (VIDAS® IFNy RUO, bioMérieux). The 820 positivity range was 0.08 -8 IU/mL and IFA positivity thresholds were defined at 0.08 IU/mL. 821 The IFNy response was defined as positive when the IFNy concentration of the test was above 822 threshold and the negative control was below threshold or when the IFNy concentration of the 823 test minus IFNy concentration of the negative control was above threshold. All positive controls 824 were $\geq 8 \text{ IU/mL}$.

825

826 Reagents: culture media, cytokines, ELISA and multiplex assays. PBMC isolation. Blood 827 samples were collected in heparinized tubes BD Vacutainer® LH 170 U.I., from Dutscher (catalog reference: 367526), diluted in PBS 1X purchased from Eurobio Scientific (catalog 828 reference: CS3PBS01-01) and transferred in Leucosep^{TM-} 50mL purchased from Greiner Bio-829 830 One (catalog reference: 227290). Blood was centrifuged using MF48-R Centrifuge from AWEL Industries (catalog reference: 20023001). PBMC were collected in Centrifuge tube 831 832 50mL TPP from Dutscher (catalog reference: 91050), washed with PBS 1X, resuspended in CryoStor[®] CS10 purchased from STEMCELLTM technologies (catalog reference: 5100-0001) 833 and transferred in CryotubeTM vials from ThermoFisher Scientific (catalog reference: 377267). 834 835 Samples were finally conserved for 24h at -80°C in a cryo-freezing container Mr.FrostyTM from 836 Thermo Fisher Scientific before storage in liquid nitrogen. Cross-presentation assay or peripheral blood lymphocyte stimulation with autologous monocyte derived- dendritic cells 837 838 (DC). Frozen PBMCs were thawed, washed and resuspended in RPMI Medium 1640 (1X) 839 purchased from GIBCO (catalog reference: 31870-025). Counting and viability were evaluated

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

using Vi-CELLTM XR Cell Viability Analyzer from Beckman Coulter (catalog reference: 840 AV13289). To separate adherent and non-adherent cell populations, PBMC were transferred in 841 842 6 or 24 well flat bottom Sterile tissue culture testplate TPP purchased from Dutscher (catalog 843 reference: 92006 / 92024) and cultured in complex medium (Complex Medium 1) containing 844 human AB serum (catalog reference: 201021334), purchased from Institut de Biotechnologies 845 Jacques Boy France), RPMI Medium 1640 (1X) (catalog reference: 31870-025), Sodium Pvruvate (catalog reference: 11360-039), Penicillin /Streptomycin (catalog reference: 15140-846 122), L-Glutamine (200mM) (catalog reference: 25030-024) HEPES Buffer Solution (catalog 847 848 reference: 15630-056), MEM NEAA (catalog reference: 1140-035), purchased from GIBCO/ThermoFisher Scientific. The Non-adherent fraction was cultured in another complex 849 850 medium (Complex Medium 2) containing human AB serum, Iscove's Modified Dulbecco's 851 Medium (catalog reference: I3390), from Sigma-Aldrich, Sodium Pyruvate (catalog reference: 852 11360-039), Penicillin/Streptomycin (catalog reference: 15140-122), L-Glutamine (200mM) (catalog reference: 25030-024) HEPES Buffer Solution (catalog reference: 15630-056), MEM 853 854 NEAA (catalog reference: 1140-035) from GIBCO/ThermoFisher Scientific and Recombinant 855 Human IL-2 (PHAR000306) from Gustave Roussy Institute pharmacy. The adherent fraction 856 was differentiated into monocyte derived- dendritic cells (mo-DC) in a mo-DC differentiating 857 media constituted with Complex Medium 1 supplemented with Recombinant Human GM-CSF Premium purchased from Miltenyi (catalog reference: 130-093-867) and human IFNa-2b 858 (Introna) purchased from MSD (France) (catalog reference: PHAR008943). For activation and 859 maturation, DCs were stimulated with LPS purchased from Invivogen (catalog reference:) and 860 GM-CSF purchased from Miltenvi Biotec (catalog reference: 130-093-867). PBL and mo-DC 861 were finally co-cultured into 96 well V bottom Sterile NuncTM plate, VWR purchased from 862 Dutscher (catalog reference: 92097). For positive control, PBL were stimulated with 863 DynabeadsTM Human T-Activator CD3/CD28 purchased from GIBCO / ThermoFisher 864 Scientific (catalog reference: 11131D). All cell cultures were performed at 37°C, 5% CO₂ into 865 Heraus[®] incubator purchased from Kendro Laboratory Products, ThermoFisher Scientific 866 (catalog reference: BB 6220) And supernatants were transferred into 96 well V bottom Sterile 867 NuncTM plate, VWR purchased from Dutscher (catalog reference: 734-0491) and frozen. 868 Peptide-based assay. 96 well V bottom Sterile NuncTM plate were coated with peptides at 869 2µg/mL in RPMI Medium 1640 (1X) (catalog reference: 31870-025) supplemented with 1% 870 871 Penicillin/Streptomycin (catalog reference: 15140-122) and conserved at -80°C. PBMCs were 872 then thawed and plated in plate containing peptides in RPMI Medium 1640 (1X) (catalog reference: 31870-025) supplemented with 1% Penicillin/Streptomycin (catalog reference: 873 874 15140-122) supplemented with Recombinant Human IL-15 Premium grade from Miltenyi 875 biotec (catalog reference: 130-095-765) and Recombinant Human IL-2 (PHAR000306) from 876 Gustave Roussy Hospital. For positive, PBMC were stimulated with functional grade CD3, 877 OKT3 purchased from ThermoFisher Scientific (catalog reference: 16-0037-85). Cell cultures 878 were then supplemented with human AB serum (catalog reference: 201021334) purchased from 879 Institut de Biotechnologies Jacques Boy (France) and cultured at 37°C, 5% CO₂. Cytokines 880 monitoring. Supernatants from cultured cells from Cross-presentation assay were monitored 881 using the MACSPlex Cytokine 12 Kit human purchased from Miltenyi Biotec (catalog reference: 130-099-169). Acquisitions and analyses were performed on CytoFLEX S purchased 882 883 from Beckman Coulter (catalog reference: B75442)/FACSAria Fusion purchased from

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

BDbiosciences and FlowJo Software from Treestar respectively. Whereas Supernatants from
cultured cells from peptide-based assay were monitored using ELISA tests purchased from
BioLegend: ELISA MAXTM Deluxe Set Human IFN-γ (catalog reference: 430104) ELISA
MAXTM Deluxe Set Human IL-17 (catalog reference: 433914) and ELISA MAXTM Deluxe Set
Human IL-9 (catalog reference: 434705).

889

890 Rationale of peptide selection and peptide synthesis (Refers to Table S6). Peptide selection 891 and synthesis: the peptides from the spike and nucleocapsid proteins were selected by dividing 892 the sequences of the SARS-CoV-2 spike protein (RefSeq ID OHD43416.1) and of the 893 nucleocapsin protein (RefSeq ID QHD43423.2) in non-overlapping 15 amino acid segments. 894 The peptides from the membrane protein were selecting by dividing the sequence of 2 potential 895 immunogenic regions of the SARS-CoV-2 (RefSeq QHD43422.1) membrane protein in 896 overlapping 15 amino acid segments. The peptides from the ORF8 and ORF10 proteins were 897 selected by dividing the sequences of the SARS-CoV-2 ORF8 protein (RefSeq ID 898 QHD43422.1) and of the ORF10 protein (RefSeq ID QHI42199.1) in overlapping 15 amino 899 acid segments. The peptides from ORF3 and some for ORF8 were selected based on a previous 900 study [81]. The SARS-CoV-1peptides were peptides found to be immunogenic in previous 901 reported studies. The peptides were synthesized by peptides&elephants GmbH (Berlin, 902 Germany). The peptide pools for the controls for Influenza, EBV and CMV were acquired from 903 peptides&elephants GmbH (Berlin, Germany) order numbers LB01774, LB01361 and 904 LB01232 respectively.

905 906

907 Statistical analysis. All calculations, statistical tests, and data visualization were performed 908 using R v4.0.3. All analyses were performed on independent samples, excepting when the 909 presence of replicates is mentioned. The associations between continuous variables were 910 evaluated using Spearman correlation. Group comparisons were performed using non-911 parametric test with the wilcox.test R function: the Wilcoxon-Mann-Whitney test for 912 independent samples, and the Wilcoxon signed rank test for paired samples. The comparison 913 of categorical data was performed using the Fisher exact test with the fisher test R function. 914 Hierarchical clustering was performed with the package hclust, using the euclidean distance. 915 Linear and logistic regressions were performed with respectively the lm and the glm R base 916 functions. A peptide set enrichment analysis was performed with the R package fgsea (version 917 1.14.0), using as statistic the t-value of the coefficient of univariable linear regressions of the 918 logarithm-normalized IL-2 secretion on the different peptides. All hypothesis tests (including 919 those of regression coefficients) were two-sided and considered as statistically significant when 920 p<0.05. Graphical illustrations were drawn using the standard R packages dedicated to the data 921 visualization (ggplot2, ggpubr, corrplot, complexheatmap, circlize, and Hmisc).

922

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

Acknowledgments: We thank the ET-EXTRA team (Biological Resource Center (NF 96-600) and the microbiology team for technical help. We thank the staff from health and safety of Gustave Roussy Cancer Campus for helping to set up the translational research studies. We are thankful to the Genalyte for their supportive help. We are thankful to Jeanne Magnan and Alexandre Trubert for their supportive help. Lyon COVID Study GROUP and authors thank the Hospices Civils de Lyon and by Fondation des Hospices Civils de Lyon and all the personnel of the occupational health and medicine department of Hospices Civils de Lyon who contributed to the samples collection.

- 930 Contributions: L.D., L.Z., A.M. and F.B. conceived and designed the clinical trial. L.Z. conceived and designed 931 the translational research, interpreted the data and formulated figure design. A.G., F-X.D., S.T., C.M., L.A., B.B., 932 A.St., B.G., M.Mer., F.S., A.M., L.D. included patients in the clinical trial. J-E.F, I.L., A.C., M.Maz., C.T., Y.H., 933 M.Pi., M.G., B.K., G.F., A.D., C.F., A.T. and J.M. carried out all the experiments. J-E.F., and D.D. performed all 934 the statistical analyses. L.D., A.G. C.A-C-S. and G.M collected the clinical data. Sophie Assan provided the 935 information from the HCL series with the contribution of BioMérieux. C.M , B.L.S., S.G. and S.C. analyzed and 936 provided the clinical data from the IHU. E.C. and F.G. performed the RT-qPCR. A-G.G., C. A-C-S., M.Maz. and 937 LD collected the biological data (ALC and Ct values). C.P. collected the samples. M.Maz., Y.H., E.P., C.F., G.F., 938 C.T., A-G.G., B.K., A.T., and P.L. prepared the biological samples and provided some help for the experiments. 939 B.L.S performed the viral cultures and provided viral lysates. A-A.B. helped with experiments performed in a 940 BSL-3 confined environment. M.Mi. and G.G. performed the dosages of antibodies. E.d.S, MM and J.R.L 941 designed the epitopes and prepared the peptides. All the authors advised for the interpretation of the data. L.Z. 942 wrote the manuscript, with all authors contributing to writing and providing feedback.
- 943

944 Funding: L.D. has received support by the Philanthropia Fondation Gustave Roussy. The Gustave Roussy 945 sponsored clinical study on COVID-19 (ONCOVID; NCT NCT04341207 has been supported by the Fondation 946 Gustave Roussy, the Dassault family, Malakoff Humanis, Agnès b., Izipizi, andRalph Lauren. A-G.G. and I.L. 947 were supported by Fondation pour la Recherche Médicale (FRM). Lyon COVID study GROUP are Biomerieux 948 employees or received grant from Bioméireux to perform experiments. L.Z. and G.K. were supported by RHU 949 Torino Lumière (ANR-16-RHUS-0008), ONCOBIOME H2020 network, the SEERAVE Foundation, the Ligue 950 contre le Cancer (équipe labelisée); Agence Nationale de la Recherche - Projets blancs; ANR under the frame of 951 E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); 952 Cancéropôle Ile-de-France; FRM; a donation by Elior; the European Research Council (ERC); Fondation 953 Carrefour; High-end Foreign Expert Program in China (GDW20171100085 and GDW20181100051), Institut 954 National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx 955 Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination 956 (SOCRATE); CARE network (directed by Prof. Mariette, Kremlin Bicêtre AP-HP), and the SIRIC Cancer 957 Research and Personalized Medicine (CARPEM).

958

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

959 G.I. and M.P. were supported by Italian Ministry of Health (grants Ricerca CorrenteLinea 1, 1 'Infezioni 960 Emergenti e Riemergenti', projects COVID-2020-12371675 and COVID-2020-12371817). M.Mi and G.G. were 961 supported by ANR Flash COVID-19 program and ARS-CoV-2 Program of the Faculty of Medicine from Sorbonne 962 University ICOViD programs (PI: G.G.). M.Mer. is a member of the Gates Foundation's innate immunity advisory 963 group and his work is supported by the Champalimaud Foundation through funds from grants UIDB/04443/2020, 964 LISBOA-01-0145-FEDER-022231 and LISBOA-01-0246-FEDER-000007. Over the last 5 years: AM has been a 965 Principal Investigator of Clinical Trials from the following companies: Roche/Genentech, BMS, Merck (MSD), 966 Pfizer, Lytix pharma, Eisai, Astra Zeneca/Medimmune, Tesaro, Chugai, OSE immunotherapeutics, SOTIO, 967 Molecular Partners, IMCheck, Pierre Fabre, Adlai Nortye. A.M. has been a Member of Clinical Trial Steering 968 Committees for NCT02528357 (GSK), NCT03334617 (AZ) and a Member of Data Safety and Monitoring Board: 969 NCT02423863 (Sponsor: Oncovir), NCT03818685 (Sponsor: Centre Léon Bérard). A.M. has been a compensated 970 member of the following Scientific Advisory Boards : Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin 971 Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, Tesaro/GSK, Oncosec, Pfizer, Seattle 972 Genetics, Astra Zeneca/Medimmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi, 973 Pierre Fabre, RedX pharma, OSE Immunotherapeutics, Medicxi, HiFiBio, IMCheck, MSD, iTeos, Innate Pharma, 974 Shattuck Labs, Medincell, Tessa Therapeutics, Deka Biosciences. A.M. has provided compensated 975 Teaching/Speaker activities for Roche/Genentech, BMS, Merck (MSD), Merck Serono, Astra 976 Zeneca/Medimmune, Amgen, Sanofi, Servier. AM has provided compensated Scientific & Medical Consulting 977 for Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Genticel, Rigontec, Daichii Sankyo, Imaxio, Sanofi/BioNTech, 978 Molecular Partners, Pillar Partners, BPI, Faron, Applied Materials. AM has benefited of Non-Financial Support 979 (travel expenses) from Astra Zeneca, BMS, Merck (MSD), Roche. A.M. is a shareholder of Pegascy SAS, Centessa 980 Pharmaceuticals, HiFiBio, Shattuck Labs. A.M. has received pre-clinical and clinical research grants (Institutional 981 Funding) from Merus, BMS, Boehringer Ingelheim, Transgene, Fondation MSD Avenir, Sanofi and Astra Zeneca. 982 BLS has received founding from the French Government under the "Investments for the Future" programme 983 managed by the National Agency for Research (ANR), Méditerranée-Infection 10-IAHU. E.D. reports grants and 984 personal fees from ROCHE GENENTECH, grants from SERVIER, grants from ASTRAZENECA, grants and 985 personal fees from MERCK SERONO, grants from BMS, grants from MSD, grant and personal fees from 986 Boehringer and was supported by INCa 2018-1-PL BIO-06-1 outside the submitted work. J-P.S was supported by 987 MSD Avenir and has received and personal fees from Roche, MSD, BMS, Lilly, AstraZeneca, Daiichi-Sankyo, 988 Mylan, Novartis, Pfizer, PFO, LeoPharma and Gilead outside the submitted work.

989 The authors declare the following competing interests: L.Z. and G.K. are cofounders of everImmune, a biotech 990 company devoted to the use of commensal microbes for the treatment of cancers. A.G., A.B.T. and A.M. as part 991 of the Drug Development Department (DITEP) are Principal/sub-Investigator of Clinical Trials for Abbvie, 992 Adaptimmune, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex 993 Pharmaceuticals, Astra Zeneca, Astra Zeneca Ab, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, 994 Bioalliance Pharma, Biontech Ag, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol 995 Myers Squibb, Bristol-Myers Squibb International Corporation, Ca, Celgene Corporation, Cephalon, Chugai 996 Pharmaceutical Co., Clovis Oncology, Cullinan-Apollo, Daiichi Sankyo, Debiopharm S.A., Eisai, Eisai Limited, 997 Eli Lilly, Exelixis, Forma Tharapeutics, Gamamabs, Genentech, Gilead Sciences, Glaxosmithkline, Glenmark 998 Pharmaceuticals, H3 Biomedicine, Hoffmann La Roche Ag, Incyte Corporation, Innate Pharma, Institut De

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

999 Recherche Pierre Fabre, Iris Servier, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin 1000 Pharm. Dev., Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Kgaa, 1001 Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular 1002 Partners Ag, Nanobiotix, Nektar Therapeutics, Nerviano Medical Sciences, Novartis Pharma, Octimet Oncology 1003 Nv, Oncoethix, Oncomed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Ose Pharma, 1004 Pfizer, Pharma Mar, Philogen S.P.A., Pierre Fabre Medicament, Plexxikon, Rigontec Gmbh, Roche, Sanofi 1005 Aventis, Sierra Oncology, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Tioma Therapeutics, Wyeth 1006 Pharmaceuticals France, Xencor, Y's Therapeutics, Research Grants from Astrazeneca, BMS, Boehringer 1007 Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi. Non-financial support (drug supplied) from 1008 Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, 1009 Pfizer, Roche. N.L. reports to be a Speaker at Jazz Pharmaceutical. Lyon COVID study GROUP are Biomerieux 1010 employees or received grant from Bioméireux to perform experiments. F.S. reports consulting fees from Pfizer, 1011 BMS, MSD, Roche, Pierre Fabre Oncology, Leo Pharma, Bayer, Mylan/Viatris, Mundi Pharma, Vifor Pharma, 1012 Biogaran, Helsinn. D.D. reports consulting fees from Chugai and Roche. E.D. reports grants and personal fees 1013 from ROCHE GENENTECH, grants from SERVIER, grants from ASTRAZENECA, grants and personal fees 1014 from MERCK SERONO, grants from BMS, grants from MSD, grant and personal fees from Boehringer outside 1015 the submitted work. F.B. reports personal fees from Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer-1016 Ingelheim, Eli Lilly Oncology, Hoffmann-La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer and 1017 Takeda, outside the submitted work. J-C.S. was a full-time employee of AstraZeneca between September 2017 1018 and December 2019. J-C.S. reports consultancy: Relay Therapeutics, Gritstone Oncology and shares: Gritstone, 1019 AstraZeneca, Daiichi-Sankyo, outside the submitted work. G.G. is a member of the scientific board of Luxia 1020 Scientific and reports consultancy for Pileje and Luxia Scientific, outside the submitted work.

1021 Figure Legends

1022

1023 Figure 1. SARS-CoV-2 TH1/TC1 responses in COVID-19 and unexposed individuals.

1024 A. Graphical representation of the prospective patient cohorts used for the study (refer to Table 1025 S1 and Table S2). B. First experimental in vitro stimulation assay of peripheral blood lymphocytes (PBL) using cross-presentation of viral lysates by autologous dendritic cells (DC). 1026 1027 Twelve plex flow cytometric assay to monitor cytokine release in replicates. C. Mean fold changes (Log2, F.C) between SARS-CoV-2-specific cytokine secretions of acute COVID-19 1028 1029 patients or convalescent COVID-19 individuals and controls (also refer to S1C). **D.** Ratios of 1030 cytokine secretion between PBL stimulated with DC pulsed with SARS-CoV-2 (or the other CCC lysates) versus VeroE6 (or versus CCC respective control cell lines), at the acute or 1031 convalescent phases of COVID-19. One typical example is outlined in Figure S1A. Each dot 1032 represents the mean of replicate wells for one patient (Controls, n=304; Convalescent COVID-1033 19, n=54; Acute COVID-19, n=24). Asterisks indicate statistically significant differences in 1034 1035 comparison to the control group determined using two-sided Wilcoxon-Mann-Whitney test

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

28

1036 (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). **E.** Spearman correlations between SARS-1037 CoV-2-specific IL-2 (left panel) or IL-5 (right panel) release and anti-NC IgG antibody titers 1038 (Controls, n=63; Convalescent, n =16).

1039

Figure 2. Unexposed individuals susceptible to COVID-19 exhibited a SARS-CoV-2 specific TH2 profile during the first surge of the pandemic.

1042 **A-B.** Upper scheme: Outline of the prospective collection of blood samples used to identify 1043 COVID-19 resistant (yellow) versus susceptible (red) cancer patients (A, upper panel, Table 1044 S1, Table S4) and pie chart indicating the absolute numbers (and %) of patients reported as 1045 contact (resistant) or infected (susceptible) or unexposed (green) during one-year follow-up (B). Lower scheme: Outline of the prospective collection of blood samples used for the 1046 comparison of T cell responses in the cohort of cancer-free individuals who lived in the same 1047 1048 household with family members tested positive for COVID-19 during the 2020 lock down 1049 (Table S3). C. Number of positive cytokines released by SARS-CoV-2-specific PBL during the 1050 cross-presentation assay (Figure 1B) in each group (Unexposed, n=159; Resistant, n=48; 1051 Susceptible, n=22). D-E. SARS-CoV-2-specific IL-2 (left panel) and IL-5 (right panel) 1052 secretion contrasting resistant (yellow) versus infected (red) cases. Each dot represents the ratio (D) of the replicate wells in one individual and the box plots indicate medians, 25th and 75th 1053 1054 percentiles for each patient subset. The bar plots (E) represent the percentage of positive 1055 patients (resist., n=41; suscept., n=19). Fisher exact test to compare the number of cytokine 1056 positive patients across groups (*p < 0.05). F. SARS-CoV-2-specific IL-2/IL-5 ratios 1057 (means+SEM) in the different subsets presented in panel A. Refer to Figure S4 for the waterfall 1058 plots to visualize variations in the percentages of individuals with IL-2/IL-5 ratios > or < 11059 according to subject category. G. CCC (OC43 and 229E)-specific IL-2 ratio (left panel) or IL-1060 5 secretion ratio (right panel) contrasting contact (resistant, yellow dots, n=34) versus infected 1061 (susceptible, red dots, n=11) cases. H. Spearman correlations between OC43 and SARS-CoV-1062 2-specific IL-2 (left panel) and IL-5 (right panel) secretions in 156 controls. I. Anti-spike IgG titers (means+SEM) specific of seasonal betacoronaviruses in contact (resist., yellow dots, 1063 1064 n=34) versus infected (suscept., red dots, n=11) cases. J. Scheme detailing the two groups of 1065 cancer-free individuals from the same hospital with opposite clinical phenotypes (multi-1066 exposed individuals (n=12) versus patients re-infected with SARS-CoV-2 (n=17) patients) (J. 1067 left panel). Results of the cross-presentation assay against SARS-CoV-2 for IL-10 (J, right 1068 panel) and IL-2 (refer to Figure S5B). IL-5 levels at baseline and after TCR cross-linking are 1069 depicted in the middle panel. Each dot represents the mean of two replicates for one patient.

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

29

1070 All group comparisons were performed using two-sided Wilcoxon-Mann-Whitney test and 1071 asterisks indicate statistically significant differences (*p<0.05, **p<0.01, ***p<0.001, 1072 ****p<0.0001).

1073

Figure 3. Peptide recognition patterns in all distinct subsets of individuals: repertoire breadth of peptide does not predict resistance to COVID-19.

- 1076 A. Experimental setting for the 186 peptide-based *in vitro* stimulation assays. B. Bicolor map 1077 of peptide recognition (positive in salmon, negative in purple, not determined in grey). Patients (n=164) were ordered in columns by unsupervised hierarchical clustering and peptides were 1078 1079 ordered on rows according to recognition frequency. The left column details clinical information and the upper line indicates the peptide frequency and the names of the proteins. 1080 1081 C-D. Percentages of positive peptides in individuals from the pre-COVID19 era (n=23) versus contemporary controls (n=100) (C, right panel) and in cancer (n=112) versus cancer free 1082 contemporary individuals (n=13) (C, left panel) and in uninfected (control, n=123) versus 1083 1084 convalescent (recovery, n=25) (D, left panel) and resistant individuals (non-infected contact 1085 cases (n=45) versus susceptible (infected, n=18) individuals (D, right panel). Group comparisons were performed using two-sided Wilcoxon-Mann-Whitney test and asterisks 1086 indicate statistically significant differences (*p<0.05, **p<0.01, ***p<0.001, ***p<0.0001). 1087 1088
- Figure 4. Receptor Binding Domain (RBD)-directed TH1/TC1 recall responses predict
 resistance to COVID-19.
- A. Linear regression analysis of the relative contribution (t-value corresponding to the 1091 1092 regression coefficient) of each peptide to SARS-CoV-2-specific TH1/TC1 responses (measured 1093 as IL-2 secretion in responses to whole virus lysate in Fig. 1), as determined in the peptide-1094 specific IFNy secretion assay in 123 COVID-19 negative individuals. Statistically significant 1095 peptides (p < 0.05) are annotated with asterisks (A, left panel). Peptides colored in blue 1096 reportedly harbor at least one mutation within SARS-CoV-2 variants (Table S7). Peptide set 1097 enrichment analysis plot (A, right panel). The contribution of each peptide to the SARS-CoV-1098 2-specific IL-2 secretion was used to rank 164 peptides. The enrichment score of S1-RBD 1099 peptides suggested that this peptide set presented lower t-values than randomly expected 1100 (p=0.048) (A, right panel). B-C. Percentages of patients recognizing at least one S1-RBD 1101 peptide in the IFNy ELISA of the peptide IVS assay across patients' groups described in Figure 2A (B) or convalescent versus re-infected patients (C). **D.** Percentages of patients recognizing 1102 1103 at least one S1-RBD peptide in the IFNv ELISA of the peptide IVS assay in cancer and cancer

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

1104 free patients from the pre-COVID19 era. E. Percentages and absolute numbers of mutations 1105 contained in our S1-RBD peptide list reported in the current SARS-CoV-2 variants (refer to Table S7). The difference of the probability of mutation in S1-RBD region and in other regions 1106 1107 was evaluated using logistic regression (Odd Ratio=0.21, 95% confidence interval [0.06; 0.68], 1108 p=0.01). F. IFNy levels in whole blood samples from a cohort of COVID-19 negative or 1109 positive (convalescent) HCW (refer to Table S10) drawn pre- and post- vaccines, that were 1110 measured after a 22-hour stimulation with mitogens using a pool of overlapping RBD peptides 1111 (BioMérieux assay). Group comparisons were performed using two-sided paired Wilcoxon-1112 Mann-Whitney test and asterisks indicate statistically significant differences (*p<0.05, ***p*<0.01, ****p*<0.001, *****p*<0.0001). 1113 1114 1115 1116 **References:** 1117 1118 1. Chen, Z. & John Wherry, E. T cell responses in patients with COVID-19. Nat Rev 1119 Immunol 20, 529–536 (2020). 1120 2. Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384, 403–416 (2021). 1121 3. Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N 1122 1123 Engl J Med 383, 2603–2615 (2020). 4. Walsh, E. E. et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine 1124

4. Walsh, E. E. *et al.* Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *N Engl J Med* 383, 2439–2450 (2020).
5. Dilich T. *et al.* T call and article dulingting delineate SADS. CoV. 2 mention. If it is

5. Bilich, T. *et al.* T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. *Sci. Transl. Med.*1128 13, eabf7517 (2021).

1125

1133

1134

- 11296. Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by
vaccine-induced humoral immunity.1131http://medrxiv.org/lookup/doi/10.1101/2021.02.14.21251704(2021)1132doi:10.1101/2021.02.14.21251704.(2021)
 - 7. Moore, J. P. Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy. *JAMA* **325**, 1251 (2021).
- Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K. & Perlman, S. Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus Infection. *Journal of Virology* 88, 11034–11044 (2014).
- 1139
 9. Le Bert, N. *et al.* SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS,and uninfected controls. *Nature* 584, 457–462 (2020). 1.
 1141
 10. Ng, O.-W. *et al.* Memory T cell responses targeting the SARS coronavirus persist up to
- 114110. Ng, O.-W. *et al.* Memory T cell responses targeting the SARS coronavirus persist up to114211 years post-infection. Vaccine **34**, 2008–2014 (2016).
- 114311. Zhao, J. et al. Airway Memory CD4 + T Cells Mediate Protective Immunity against1144Emerging Respiratory Coronaviruses. Immunity 44, 1379–1391 (2016).
- 1145
 12. Mosmann, T. R. & Coffman, R. L. TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties. *Annu. Rev. Immunol.* 7, 1147
 145–173 (1989).

1148	13	. Romagnani, S. Biology of human TH1 and TH2 cells. J Clin Immunol 15, 121–129
1149		(1995).
1150	14	. Romagnani, S. & Maggi, E. ThI versus Th2 responses in AIDS. Current Opinion in
1151		Immunology 6 , 616–622 (1994).
1152	15	. Ruterbusch, M., Pruner, K. B., Shehata, L. & Pepper, M. In Vivo CD4 + T Cell
1153		Differentiation and Function: Revisiting the Th1/Th2 Paradigm. Annu. Rev. Immunol.
1154		38 , 705–725 (2020).
1155	16.	. Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months
1156		after infection. Science 371 , eabf4063 (2021).
1157	17.	. Habel, J. R. <i>et al</i> . Suboptimal SARS-CoV-2-specific CD8 ⁺ T cell response
1158		associated with the prominent HLA-A*02:01 phenotype. Proc Natl Acad Sci USA 117,
1159		24384–24391 (2020).
1160	18	. Oxford Immunology Network Covid-19 Response T cell Consortium et al. Broad and
1161		strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent
1162		individuals following COVID-19. Nat Immunol 21, 1336–1345 (2020).
1163	19	. Rodda, L. B. et al. Functional SARS-CoV-2-Specific Immune Memory Persists after
1164		Mild COVID-19. Cell 184, 169-183.e17 (2021).
1165	20	Sekine, T. et al. Robust T Cell Immunity in Convalescent Individuals with
1166		Asymptomatic or Mild COVID-19. Cell 183, 158-168.e14 (2020).
1167	21	. Bacher, P. et al. Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed
1168		Individuals and Humans with Severe COVID-19. Immunity 53, 1258-1271.e5 (2020).
1169	22.	Lee, JS. et al. Evidence of Severe Acute Respiratory Syndrome Coronavirus 2
1170		Reinfection After Recovery from Mild Coronavirus Disease 2019. Clinical Infectious
1171		Diseases ciaa1421 (2020) doi:10.1093/cid/ciaa1421.
1172	23.	Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with
1173		COVID-19. Nature 587, 270–274 (2020).
1174	24	. Grifoni, A. et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans
1175		with COVID-19 Disease and Unexposed Individuals. Cell 181, 1489-1501.e15 (2020).
1176	25	. Dykema, A. G. et al. Functional characterization of CD4+ T cell receptors crossreactive
1177		for SARS-CoV-2 and endemic coronaviruses. Journal of Clinical Investigation 131,
1178		e146922 (2021).
1179	26	. Goubet, AG. et al. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are
1180		hallmarks of COVID-19 in cancer patients with poor prognosis.
1181		http://medrxiv.org/lookup/doi/10.1101/2021.04.26.21250357 (2021)
1182		doi:10.1101/2021.04.26.21250357.
1183	27	Andre, F. et al. Malignant effusions and immunogenic tumour-derived exosomes. The
1184		Lancet 360 , 295–305 (2002).
1185	28	. Besse, B. et al. Dendritic cell-derived exosomes as maintenance immunotherapy after
1186		first line chemotherapy in NSCLC. OncoImmunology 5, e1071008 (2016).
1187	29	Borg, C. et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK
1188		cell-dependent antitumor effects. J. Clin. Invest. 114, 379–388 (2004).
1189	30	Wemeau, M. et al. Calreticulin exposure on malignant blasts predicts a cellular
1190		anticancer immune response in patients with acute myeloid leukemia. <i>Cell Death Dis</i> 1.
1191		e104–e104 (2010).
1192	31	Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed
1193	01	humans. Science 370 . 89–94 (2020).
1104	22	Nolda A at al SADS CoV 2 derived portidas define beterologous and COVID 10

1194
 32. Nelde, A. *et al.* SARS-CoV-2-derived peptides define heterologous and COVID-19 induced T cell recognition. *Nat Immunol* 22, 74–85 (2021).

31

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

32

1196 33. Le Bert, N. et al. Highly functional virus-specific cellular immune response in 1197 asymptomatic SARS-CoV-2 infection. Journal of Experimental Medicine 218, 1198 e20202617 (2021). 1199 34. Zhao, Y. et al. Clonal expansion and activation of tissue-resident memory-like T_H 17 1200 cells expressing GM-CSF in the lungs of patients with severe COVID-19. Sci. Immunol. 1201 6, eabf6692 (2021). 35. Fournier, P.-E. et al. Emergence and outcomes of the SARS-CoV-2 'Marseille-4' 1202 variant. International Journal of Infectious Diseases 106, 228-236 (2021). 1203 1204 36. Cha, E. et al. Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 1205 Treatment in Cancer Patients. Science Translational Medicine 6, 238ra70-238ra70 1206 (2014).1207 37. Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire 1208 in human cancers. Nat Med 25, 89-94 (2019). 1209 38. Yager, E. J. et al. Age-associated decline in T cell repertoire diversity leads to holes in 1210 the repertoire and impaired immunity to influenza virus. Journal of Experimental Medicine 205, 711–723 (2008). 1211 39. Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 1212 1213 221–224 (2020). 1214 40. Low, J. S. et al. Clonal analysis of immunodominance and cross-reactivity of the CD4 1215 T cell response to SARS-CoV-2. Science eabg8985 (2021) 41. Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639-1216 1217 644 (2021). 1218 42. Mouton, W. et al. A novel whole-blood stimulation assay to detect and quantify memory 1219 T-cells COVID-19 patients. in 1220 http://medrxiv.org/lookup/doi/10.1101/2021.03.11.21253202 (2021)doi:10.1101/2021.03.11.21253202. 1221 43. Whitmire, J. K., Asano, M. S., Murali-Krishna, K., Suresh, M. & Ahmed, R. Long-Term 1222 1223 CD4 Th1 and Th2 Memory following Acute Lymphocytic Choriomeningitis Virus 1224 Infection. J Virol 72, 8281–8288 (1998). 1225 44. Hondowicz, B. D., Kim, K. S., Ruterbusch, M. J., Keitany, G. J. & Pepper, M. IL-2 is 1226 required for the generation of viral-specific CD4⁺ Th1 tissue-resident memory cells and B cells are essential for maintenance in the lung. Eur. J. Immunol. 48, 80–86 (2018). 1227 1228 45. Li, C. K. et al. T Cell Responses to Whole SARS Coronavirus in Humans. J Immunol 1229 181, 5490–5500 (2008). 1230 46. Page, C. et al. Induction of Alternatively Activated Macrophages Enhances 1231 Pathogenesis during Severe Acute Respiratory Syndrome Coronavirus Infection. 1232 Journal of Virology 86, 13334–13349 (2012). 1233 47. Yale IMPACT Team et al. Longitudinal analyses reveal immunological misfiring in 1234 severe COVID-19. Nature 584, 463-469 (2020). 1235 48. Kumamoto, Y. et al. CD301b+ Dermal Dendritic Cells Drive T Helper 2 Cell-Mediated 1236 Immunity. Immunity 39, 733–743 (2013). 1237 49. Sokol, C. L., Camire, R. B., Jones, M. C. & Luster, A. D. The Chemokine Receptor 1238 CCR8 Promotes the Migration of Dendritic Cells into the Lymph Node Parenchyma to 1239 Initiate the Allergic Immune Response. *Immunity* **49**, 449-463.e6 (2018). 1240 50. Van Dyken, S. J. et al. A tissue checkpoint regulates type 2 immunity. Nat Immunol 17, 1381-1387 (2016). 1241 1242 51. Sánchez-Cerrillo, I. et al. COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclassical monocytes. Journal of 1243 1244 Clinical Investigation 130, 6290–6300 (2020).

	6/5/21	Fahrner et al. T cell responses and COVID-19 susceptibility
1245	52.	Becattini, S. et al. Functional heterogeneity of human memory CD4+ T cell clones
1246		primed by pathogens or vaccines. Science 347, 400–406 (2015).
1247	53.	Honda, T. et al. Tuning of Antigen Sensitivity by T Cell Receptor-Dependent Negative
1248		Feedback Controls T Cell Effector Function in Inflamed Tissues. Immunity 40, 235-
1249		247 (2014).
1250	54.	. Shinoda, K. et al. Thy1 + IL-7 + lymphatic endothelial cells in iBALT provide a survival
1251		niche for memory T-helper cells in allergic airway inflammation. Proceedings of the
1252		National Academy of Sciences 113, E2842–E2851 (2016).
1253	55.	Yeon, S. et al. IL-7 plays a critical role for the homeostasis of allergen-specific memory
1254		CD4 T cells in the lung and airways. Scientific Reports 7, (2017).
1255	56.	Meckiff, B. J. et al. Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive
1256		CD4+ T Cells in COVID-19. Cell 183, 1340-1353.e16 (2020).
1257	57.	. Weiskopf, D. et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-
1258		19 patients with acute respiratory distress syndrome. Science Immunology 5, eabd2071
1259		(2020).
1260	58.	Bacher, P. et al. Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-
1261		Reactivity against Candida albicans. Cell 176, 1340-1355.e15 (2019).
1262	59.	. Greiling, T. M. et al. Commensal orthologs of the human autoantigen Ro60 as triggers
1263		of autoimmunity in lupus. Science Translational Medicine 10, eaan2306 (2018).
1264	60.	. Koutsakos, M. et al. Human CD8+ T cell cross-reactivity across influenza A, B and C
1265		viruses. Nature Immunology 20, 613–625 (2019).
1266	61.	Sridhar, S. et al. Cellular immune correlates of protection against symptomatic
1267		pandemic influenza. Nature Medicine 19, 1305–1312 (2013).
1268	62.	Welsh, R. M., Che, J. W., Brehm, M. A. & Selin, L. K. Heterologous immunity between
1269		viruses: Heterologous immunity between viruses. Immunological Reviews 235, 244-
1270		266 (2010).
1271	63.	Woodland, D. L. & Blackman, M. A. Immunity and age: living in the past? Trends in
1272		<i>Immunology</i> 27 , 303–307 (2006).
1273	64.	Tarke, A. et al. Comprehensive analysis of T cell immunodominance and
1274		immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Reports
1275		<i>Medicine</i> 2 , 100204 (2021).
1276	65.	. Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T cells associates
1277		with rapid viral clearance and mild disease in COVID-19 patients. Cell Reports 34,
1278		108728 (2021).
1279	66.	Hansen, T. H. & Bouvier, M. MHC class I antigen presentation: learning from viral
1280		evasion strategies. Nature Reviews Immunology 9, 503-513 (2009).
1281	67.	Hachim, A. et al. ORF8 and ORF3b antibodies are accurate serological markers of early
1282		and late SARS-CoV-2 infection. <i>Nature Immunology</i> 21, 1293–1301 (2020).
1283	68.	Young, B. E. et al. Effects of a major deletion in the SARS-CoV-2 genome on the
1284		severity of infection and the inflammatory response: an observational cohort study. The
1285		<i>Lancet</i> 396 , 603–611 (2020).
1286	69.	. Su, Y. C. F. et al. Discovery and Genomic Characterization of a 382-Nucleotide
1287		Deletion in ORF7b and ORF8 during the Early Evolution of SARS-CoV-2. mBio 11,
1288		(2020).
1289	70.	Greaney, A. J. et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike
1290		Receptor-Binding Domain that Escape Antibody Recognition. Cell Host & Microbe 29,
1291		44-57.e9 (2021).
1292	71.	Koenig, PA. et al. Structure-guided multivalent nanobodies block SARS-CoV-2
1293		infection and suppress mutational escape. Science 371, eabe6230 (2021).

6/5/21 Fahrner et al. T cell responses and COVID-19 suscer	ptibility
--	-----------

- 1294 72. Agerer, B. et al. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8 + T 1295 cell responses. Science Immunology 6, eabg6461 (2021). 1296
 - 73. Iwasaki, A. & Omer, S. B. Why and How Vaccines Work. Cell 183, 290-295 (2020).
- 1297 74. Bolles, M. et al. A Double-Inactivated Severe Acute Respiratory Syndrome 1298 Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased 1299 Eosinophilic Proinflammatory Pulmonary Response upon Challenge. Journal of 1300 Virology 85, 12201–12215 (2011).
- 75. Tseng, C.-T. et al. Immunization with SARS Coronavirus Vaccines Leads to Pulmonary 1301 1302 Immunopathology on Challenge with the SARS Virus. *PLoS ONE* 7, e35421 (2012).
- 1303 76. Jiang, S. et al. Roadmap to developing a recombinant coronavirus S protein receptor-1304 binding domain vaccine for severe acute respiratory syndrome. Expert Review of 1305 Vaccines 11, 1405–1413 (2012).
 - 77. Martins, K. A., Bavari, S. & Salazar, A. M. Vaccine adjuvant uses of poly-IC and derivatives. Expert Review of Vaccines 14, 447-459 (2015).
- 1308 78. Jo, W. K., Drosten, C. & Drexler, J. F. The evolutionary dynamics of endemic human 1309 coronaviruses. Virus Evolution 7, (2021).
- 1310 79. Chaput, N. et al. Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR 1311 ⁺ NK cell levels correlate with disease outcome. *OncoImmunology* **2**, e23080 (2013).
- 1312 80. Fournier, P.-E. et al. Emergence and outcomes of the SARS-CoV-2 'Marseille-4' 1313 variant. International Journal of Infectious Diseases 106, 228–236 (2021).
 - 81. Sahin, U. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature (2021) doi:10.1038/s41586-021-03653-6.
 - 82. Saini, S. K. et al. SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8 ⁺ T cell activation in COVID-19 patients. Science Immunology 6, eabf7550 (2021).
 - 83. Shomuradova, A. S. et al. SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors. *Immunity* 53, 1245-1257.e5 (2020).

1322 **Supplementary materials**

1323

1306

1307

1314

1315

1316

1317 1318

1319 1320

1321

1324 Figure S1. Cross-presentation in vitro assay at the acute and convalescent phase of COVID-19. 1325

1326 **A.** Prototypical example of the result of the assay detailed in Figure 1B and M&M for one 1327 COVID-19 negative cancer patient. Each box plot represents the absolute values of cytokine 1328 secretion of two replicate wells in the 12 plex flow cytometric assay, in the 48hr supernatants

- 1329 of PBL stimulated with DC pulsed with SARS-CoV-2 versus Vero E6 (negative control) and
- 1330 the other common cold coronaviruses and their respective control cell line (negative controls).
- 1331 Each dot represents each replicate well for each stimulatory condition for one patient. Positive
- 1332 control: PBL stimulated with anti-CD3 and anti-CD28 antibody coated beads. B. MHC class I
- 1333 and class II neutralization experiments. Neutralizing anti-HLA-ABC and HLA-DR, DP, DQ
- 1334 antibodies (W6/32 & Tu39) were used to block the specific PBL reactivities in the above assay.
- 1335 **C.** Idem as in Figure 1D showing the other 6 cytokine ratios. **D**. Spearman correlation between
- 1336 SARS-CoV-2-specific IL-2 release and non-activated TFH. Group comparisons were

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

35

1337 performed using two-sided Wilcoxon-Mann-Whitney test and the asterisks indicate statistically significant differences (**p*<0.05, ***p*<0.01, ****p*<0.001, *****p*<0.0001).

1338

1339

1340 Figure S2. Detailed SARS-CoV-2 and CCC-specific cytokine release for convalescent 1341 **COVID-19** patients compared with unexposed individuals.

- A. Non supervised hierarchical clustering of SARS-CoV-2 and CCC- specific cytokine release 1342 1343 in all patients. Heatmap of cytokine release for SARS-CoV-2 or CCC in the cross-presentation 1344 assay performed at the convalescent phase of COVID-19 (n=54) and in unexposed individuals (n=304), aligning all 12 cytokines and all subject categories. **B.** Polyfunctional T cell responses 1345 1346 among subjects from various cohorts. Individuals who exhibited SARS-CoV-2-specific release of one or several cytokines are enumerated in each bar. Each bar indicates a category of patients 1347 or subjects as described in Figure 1A. C. Percentage and number of patients in each cohort (Pre-1348 COVID19 era (ves (+)/no(-)). Cancer (ves (+)/no(-) and COVID-19 (ves (+)/no(-)) who had a 1349 1350 SARS-CoV-2-specific cytokine release (for the 5 statistically significant cytokines at the 1351 convalescent phase) compared with VeroE6 (Control, n=304; Convalescent, n=54). Asterisks 1352 indicate statistically significant differences of SARS-CoV-2-specific cytokine release 1353 proportions between two groups determined using Fisher exact test (*p < 0.05).
- 1354

1355 Figure S3. TH1/TC1 differentiation patterns in susceptible versus resistant individuals.

1356 A-B. Unsupervised hierarchical clustering of SARS-CoV-2-specific cytokine release. Heatmap 1357 of cytokine release in the cross-presentation assay performed during the first surge of the 1358 pandemic in unexposed individuals (n=60), aligning cytokines in the two subject categories, 1359 susceptible (persons who got infected during the second or the third surge of the pandemic) 1360 versus resistant (contact) individuals. Group comparisons were performed using a two-sided 1361 Wilcoxon-Mann-Whitney test, C-D. Spearman correlation matrices between cytokine levels in 1362 susceptible (n=19, C) versus resistant (n=41, D) individuals, respectively. The asterisks indicate statistically significant differences (p < 0.05). E. Dynamic study of the stability of the TH1/TH2 1363 profile in individuals that were followed up at two time points. Ratio of cytokine release at the 1364 1365 acute and convalescent phase (left panel) and corresponding IL-2/IL-5 ratio (right panel) in 5 cancer patients. Two-sided Wilcoxon-Mann-Whitney test did not reveal significant difference 1366 1367 between both time points.

1368

1369 Figure S4. Waterfall plots indicating the IL-2/IL-5 ratio in all patient or individual 1370 groups.

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

1371 Waterfall plot between IL-2 and IL-5 ratio of cytokine release in the Figure 1B IVS assay in all 1372 patients during the first surge of the pandemic depicting cancer (green) versus cancer free (blue) COVID-19+ convalescent patients (A), resistant (orange) versus susceptible (red) (B), locked 1373 1374 down (or unknown) subjects (dark green, n=301) and healthy individuals in contact with their 1375 COVID-19+ family members (light green) (D). Each bar represents one patient. Proportion of 1376 patients exhibiting an IL-2/IL-5 ratio superior or inferior to 1 is indicated in each panel. Clinical conditions are annotated as 0, +, ++, +++ for asymptomatic, mild, moderate, and severe 1377 COVID-19 severity, respectively. Refer to Figure 2F where percentages are compared 1378 1379 inbetween groups.

1380

1381 Figure S5. Cross-presentation assays using viral variants.

1382 A. Cytokine ratio in the cross-presentation assay detailed in Figure 1B, using the original strain IHUMI846 (early 2020 episode) (CoV-2 in (A)), versus the Danish mink (B.1.160, 20A.EU2, 1383 1384 GH) and North African (B1.367, 20C, GH) strains in 25 control individuals. Statistical 1385 comparisons were performed using paired two-sided Wilcoxon-Mann-Whitney test and the 1386 asterisks indicate statistically significant differences (*p < 0.05, **p < 0.01, ***p < 0.001, 1387 ****p<0.0001). **B.** Percentage and number of patients in Fig2J right panel who had a SARS-CoV-2-specific IL-2 release. Of note, only 4 re-infected patients could be tested because DC 1388 1389 could not be differentiated into monocytes in the others to allow the cross-presentation assay. C. Similar experimental setting as in Figure 1B but loading lysates from various SARS-CoV-2 1390 1391 strains (original one IHUMI846 (early 2020 episode), as well as IHUMI3076 (UK variant, 1392 B.1.1.7), IHUMI3147 (South African variant, B.1.351) and IHUMI3191 (Brazilian variant, P.1) 1393 strains isolated from human nasopharyngeal swab as previously described [35]. Heatmap of the 1394 intensity of the ratios between means of cytokine levels (of experimental replicates) obtained 1395 from PBL in coculture with DC+ IHUMI846 versus DC+ each variant.

1396

Figure S6. Percentages of patients reacting to each peptide and of peptides recognized by each individual in various groups or cohorts.

Bar plot of the percentage of patients recognizing a given peptide. Blue and green lines
represent the frequency of peptide recognition in control versus convalescent individuals
respectively. Inset. Bar plot of the percentage of positive peptides in the IFNγ ELISA per
patient. The color code indicates patient category (blue for control, green for convalescent
COVID-19, purple for re-infected patients).

1404

37

6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility

1405 Figure S7. Peptide recognition mapping in various categories of individuals.

1406 Mean frequencies of IFNy ELISA positivity in the peptide IVS assay (described in Figure 3A)

- 1407 for each indicated protein of the ORFeome in each subject category, for each individual peptide
- 1408 (each line corresponding to one peptide) in 159 subjects.
- 1409

1410 Figure S8. Correlation of secretory profiles for each peptide in the IVS assay.

Scatter plot of peptides according to the percentage of patients reacting in IFNγ or IL-9
secretion (n=43, A) IL-17 (n=23, B) or IL-5 (n=64, C). The distance to the diagonal is indicated
by a gradient of color.

1414

Figure S9. Logistic regression analyses identifying cohort -specific fingerprints of T cell repertoires.

A. Statistically significant peptide signatures in the peptide-based IVS assay (Figure 3A) using 1417 1418 a multivariable logistic regression analysis adjusted for period (pre-COVID-19 era or 1419 contemporary patients), COVID-19 history and cancer (refer to Table S2). The left column 1420 shows variables, and the x axis indicates the significant peptides (pval<0.05). The magnitude 1421 of the log (Odd Ratio) is indicated in the red/blue color code while that of the p-value is 1422 represented by the circle size. B-C. Percentages of patients recognizing at least one peptide 1423 from the pre-COVID-19 (B) or convalescent (C) signature identified in the logistic regression analyses of panel A in the IFNy ELISA in the peptide IVS assay. Fisher's exact test to compare 1424 1425 the number of patients positive for each signature between groups (*p < 0.05, **p < 0.01).

1426

1427 Supplemental Tables

1428

1429 **Table S1. Consort diagram.** Flow diagram showing the enrollment of subjects, their allocation

1430 to different cohorts and how they are analyzed in the trial.

- 1431 Table S2. Characteristics of cancer patients and healthy volunteers.
- 1432 Table S3. Characteristics of family members during the 2020 lock down.
- 1433 Table S4. Characteristics of contact (resistant) and infected (susceptible) cancer patients

1434 and corresponding swimmer plot for the outcome of the susceptible cases.

- 1435 Individual swimmer plots for each susceptible individual (*i.e.* who got infected during the
- 1436 second or the third surge of the pandemic) depicting patients still alive (blue), patients dead
- 1437 from cancer, and patients dead from COVID-19 (red) after infection indicated with an arrow.

38

- 6/5/21 Fahrner et al. T cell responses and COVID-19 susceptibility
- 1438 Table S5. Characteristics of multi-exposed cases and re-infected cancer -free individuals.
- 1439 Table S6. SARS-CoV-1 and CoV-2 or feome peptide list: sequences and positions.
- 1440 Table S7. Peptide-specific T cell polarization determined by IL-5 or IFNy quantification.
- 1441 Table S8. HLA binding affinities of the S1-RBD peptides using the NetMHCpan
- 1442 algorithm
- 1443 **Table S9. Mutational hotspots in the peptide residues.**
- 1444 Table S10. Characteristics of vaccinated healthcare workers.
- 1445
- 1446
- 1447





Figure 2





Figure 4





Β.





Figure S2









D.





Figure S3









0.1





Β.



C.





Figure S6





B.

А.

C.

Figure S8





Table S2. Characteristics of cancer patients and healthy individuals.

		Controls	(n=320)	Acute (COVID-19 (n=40)	P.value*	Convalescer	nt (n=69)	P.value #
		n	%	n	%		n	%	
	2000 - Nov. 2002	7	2	-	-		-	-	
Vaara	Nov. 2002 - 2018	61	19	-	-	< 0.01	-	-	< 0.01
Tears	Unknown	2	1	-	-	< 0.01	-	-	< 0.01
	2020 - 2021	250	78	40	100		69	100	
Age (years)	Median [Range]	61 [18-89]		63 [20-90]		0.13	56 [21-85]		0.02
Gender	Male Female	124 150	45 55	22 18	55 45	0.31	28 41	41 59	0.05
	Unknown	46	-	-	-		-	-	
Malignancy	Yes	257 63	80 20	40 0	100 0	< 0.01	40 29	58 42	< 0.01

Refers to available samples described in table S1

* : statistical analyses between controls and acute COVID-19; # : statistical analyses between controls and convalescent

Table S3. Characteristics of family members during the 2020 lockdown.

		Tat		Contract (Convoloor	ant (n=20)	Dualua
	Modian	101	a		(1-22)	Convalest	0	P.value
Age (years)	[Pango]	117	, 761	[17.7]	1	120	601	0.69
	[italige]	[17-	5]	[17-73	' 1	[20	-02]	
		n	%	n	%	n	%	
	Male	26	51	13	59	13	45	
Gender	Female	25	49	9	41	16	55	0.40
	- Cinaio	20	10	Ū		10	00	
Number of contacts per case within the family	-							
1-3				5	23	1	3	
4-6				14	64	15	52	
7-9				1	5	8	28	< 0.01
10-12				2	9	0	0	
> 12				0	0	5	17	
Number of SARS-CoV-2 positive individuals in the family								
0				4	18	0	0	
1-3				18	82	18	62	- 0.04
4-6				0	0	5	17	< 0.01
7-15				0	0	6	21	
Household size								
0				2	9	0	0	
1-2				0	0	5	17	.0.01
3-5				18	82	16	55	< 0.01
6-8				2	9	8	28	
Household living space (m ²)								
<70				7	32	6	21	
70-100				3	14	11	38	0.16
> 100				12	55	12	41	
Number of rooms in the household								
2-3				10	45	7	24	
4-5				6	27	14	48	0.22
6-8				6	27	8	28	
0-0				Ū	21	0	20	
Number of individuals using personal protective equipme	nt		_	13	59	18	62	1
a daibine a daibine								
Number of individuals respecting barriers gestures				16	73	22	76	1
Sector Se								

Table S4. Clinical characteristics of all contact cases (susceptible and resistant).



×

Ο End of follow up Death of COVID-19

		Re-infect	ed (n=17)	Multi-expose	ed cases (n=12)	P.value
Age (vears)	Median	3	7		48	0.08
	[Range]	[16-	78]	[2	8-69]	0.00
		n	%	n	%	
Gondor	Male	7	41	6	50	0.72
Gender	Female	10	59	6	50	0.72
	Yes	5	31	-	-	
Comorbidities	No	11	69	-	-	-
	Unknown	1	-	-	-	
	Asthma	3	60	-	-	
	Obesity	2	40	-	-	
Type of comorbidities	Type 2 diabetes	2	40	-	-	-
.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Cancer		20	-	-	
	HIV*	1	20	-	-	
	HBP	2	40	-	-	
	< 03	2	17	-	-	
Time to reinfection (mo)	03 - 06	7	58	-	-	_
	>06	3	25	-	-	
	Unknown	5	-	-	-	
	B.1.177	1	-	-	-	
	B.1.160	6	-	-	-	
Second surge variants	B.1.351	1	-	-	-	-
	B.1.1.7	2	-	-	-	
	Unknown	/	-	-	-	

Table S5. Characteristics of multi-exposed and re-infected cancer-free individuals.

Refers to eligible patients described in table S1

*Human Immunodeficiency Virus **High Blood Pressure Table S7. Peptide-specific T cell polarisation determined by IL-5 or IFNγ quantification.

SARS-CoV-2 protein		n	IL-5 ⁻ /IFNγ ⁻	IL-5⁺/IFNγ⁻	IL-5⁻/IFNγ ⁺	IL-5 ⁺ /IFNγ ⁺	P.value
Mombrano	Resistant	35	20	3	1	1	0.76
Membrane	Susceptible		10	0	0	0	0.70
Nucleocansid	Resistant	12	17	3	7	3	0.58
Nucleocapsiu	Susceptible	42	9	0	3	0	0.56
64	Resistant	26	15	0	9	4	0.24
31	Susceptible	30	7	0	1	0	0.34
	Resistant	26	15	3	10	0	0.06
31-KDD	Susceptible	30	8	0	0	0	0.06
60	Resistant	00	8	0	7	1	0.75
52	Susceptible	23	5	0	2	0	0.75
	Resistant	22	11	0	5	0	1.00
UKFO	Susceptible	22	4	0	2	0	1.00
	Resistant	00	15	0	1	0	0.52
URFIU	Susceptible	23	6	0	1	0	0.53
ODE2a	Resistant	22	14	0	1	0	1.00
UKFSa	Susceptible	22	7	0	0	0	1.00

The numbers correspond to the enumeration of patients who were positive for at least one of the epitopes of each protein listed in Table S6.

		Control	s (n=70)	Convales	cent (n=14)	P.value
Age (years)	Median [Range]	4 [21-	9 -76]	[28	48 3-69]	0.71
		n	%	n	%	
Gender	Male Female	18 52	26 74	2 12	14 86	0.50

Table S10. Characteristics of vaccinated healthcare workers.

Peptide name	Peptide sequence	Virus	Protein	Similar sequence in SARS-CoV-2	SARS-CoV-2 Ref seq ID	Reference	SARS-CoV-2 first position	SARS-CoV-2 last position	SARS-CoV-1 Refseq ID	SARS-CoV-1 first position
like1	MFVFLVLLPLVSSQC	SARS-CoV-2	Spike		QHD43416.1		1	15		
ike2	VNLTTRTQLPPAYTN	SARS-CoV-2	Spike		QHD43416.1		16	30		
ike3	SETROVYYPDKVERS	SARS-CoV-2	Spike		QHD43416.1		31	45		
ika4	SVLHSTQDLFLPFFS	SARS-CoV-2	Spike		QHD43416.1		40	60		
olkeS	NVTWPHAHVSGTNG	SARS-CoV-2	Spike		QHD43416.1		61	75		
ike6	TKRFDNPVLPFNDGV	SARS-CoV-2	Spike		QHD43416.1		76	90		
ike7	YFASTEKSNIRGWI	SARS-CoV-2	Spike		QHD43416.1		91	105		
pikeő	FGTTLDSKTOSLLV	SARS-CoV-2	Spike		QHD43416.1		105	120		
pike9	NNATNVVKVCEFQF	SARS-CoV-2	Spike		QHD43416.1		121	135		
pike10	CNDPFLGVYYHNNK	SARS-CoV-2	Spike		QHD43416.1		135	150		
pike11	SWMESEFRVYSSANN	SARS-CoV-2	Spike		QHD43416.1		151	165		
ike12	CTFEYVSQPFLMDLE	SARS-CoV-2	Spike		QHD43416.1		165	180		
ike13	GKOGNFKNLREFVFK	SARS-CoV-2	Spike		QHD43416.1		181	195		
pike14	NDGYFKYSKHTPI	SARS-CoV-2	Spike		QHD43416.1		195	210		
ike15	NLVRDLPQGFSALEP	SARS-CoV-2	Spike		QHD43416.1		211	225		
pike16	LVDLPIGINITRFOT	SARS-CoV-2	Spike		QHD43416.1		226	240		
pike17	LLALHRSYLTPGDSS	SARS-CoV-2	Spike		QHD43416.1		241	255		
pike18	SGWTAGAAAYYVGYL	SARS-CoV-2	Spike		QHD43416.1		256	270		
pike12	OPRTFLLKYNENGTI	SARS-CoV-2	Spike		QHD43416.1		271	285		
Spike20	TDAVDCALDPLSETK	SARS-CoV-2	Spike		QHD43416.1		285	300		
pike21	CTLKSFTVEKGIYQT	SARS-CoV-2	Spike		QHD43416.1		301	315		
olks22	SNFRVOPTEST/RFP	SARS-CoV-2	Spike		QHD43416.1		316	330		
pike23	NTNLCPFGEVFNAT	SARS-CoV-1+SARS-CoV-2	Spike		QHD43416.1		331	345	AAP41037.1	318
pike24	RFASVYAWNRKRISN	SARS-CoV-2	Spike		QHD43416.1		346	360		
pike25	CVADYSVLYNSASFS	SARS-CoV-2	Spike		QHD43416.1		361	375		
ike26	TFKCYGVSPTKLNDL	SARS-CoV-2	Spike		QHD43416.1		376	390		
ike27	CFTNVYADSFVIRGD	SARS-CoV-2	Spike		QHD43416.1		391	405		
ike28	EVROIAPGOTCKIAD	SARS-CoV-2	Spike		QHD43416.1		405	420		
jike29	YNYKLPODFTGCVIA	SARS-CoV-2	Spike		QHD43416.1		421	435		
ike30	WNSNNLDSKVGCNYN	SARS-CoV-2	Spike		QHD43416.1		435	450		
ike31	YLYRLFRIGNLIKPFE	SARS-CoV-2	Spike		QHD43416.1		451	465		
alba12	00101010101000	0100 0110			0100101001		102	480		

SAIS CAP 3
 S

SARS C

FNFNGLTGTGVLTES NOCTLPFQQFGRDIA DITDAVROPOTULEI DITPOSFGGVSVIT

> NCTEVPVAIHADO ECDIPIGAGICASYO

> LGDIAARDLICAQKF WTFGAGAALQIPFAM QMAYRFNGIGVTQNV

LYENGKLANGPNS IGKIQDSLSSTASAL GKLODV/NONADAL TLVKQLSSNFGAIS

Spike65 Spike67

kocapaid_9 kocapaid_10 kocapaid_11

capaid_15

eocapaid_18 eocapaid_19

cleocapaid_21

cleocapsid_24 cleocapsid_25

brane_1 brane_2

Mombrane, 6 Membrane, 7 8AR3_2016.05.006 8AR3_10.1128_1 8AR3_10.1128_4 8AR3_10.1128_4 8AR3_10.1128_4 8AR3_10.1128_5 8AR3_10.1128_58AR3_10.1128_58AR3_10.1128_58AR3_10000000000000000000000000000000000

SARS HLA-A'02:01 5 SARS HLA-A'02:01 6 SARS HLA-A'02:01 7

SARS_HLA-A'02:01_8 SARS_HLA-A'02:01_9 SARS_HLA-A'02:01_10

 BARS HLAAV2091 10

 BARS HLAAV2091 11

 BARS HLAAV20112

 BARS HLAAV20112

 BARS HLAAV20113

 BARS HLAAV20114

 BARS HLAAV20115

 BARS HLAAV20120

 BARS HLAAV20120

 BARS HLAAV20121

 BARS HLAAV20120

 BARS HLAAV20121

 BARS HLAAV20121

SARS HLA-DRN01 1 SARS HLA-DRN01 2 SARS HLA-DRN01 3 SARS HLA-DRN01 3 SARS HLA-DRN01 4 SARS 3726 2005 1 SARS 3726 2005 2 SARS 5314 2004 1 SARS 5314 2004 2 OREA 1

TLVKOLSSNFGAISS VLNDLSRLDKVEAE VOIDRUTGRLDSLO TVYTOOLIRAAERA SANLAATRIMSECVLG SKRVDFCGKGYHEM SEROSAENCOVELEN

CDWILIWNTYTD LQPELDSPKEELDKY PRNHTSPD/DLGDIS GNASV/NIQKEIDR LNEVAKNLNESLIDL QELGKYEQYIKWPWY

SEPVLKGVKLHY

ERSGARSKORPOGL PNNTASWFTALTOHG

REDLKFPRSGCVPN TNSSPDDQKGYYRRA TRRRGGDGKMKDLS PRWYFYYLGTGPEAG

LPYGANKDGIWVAT EGALNTPKDHIGTIN

KOPROKRTATIKAYNY TOAFGRRGPEOTOGN

WPQIAQFAPSASAFF CMRRIDMEVTPRCTW

FKDQVILLNKHIDAY KTFPPTEPKKDKXXX

HLIBACHINLORCDIK LLINGHDAYKTP PLOASLPFCWLVGV NYMYKTRURCKLIPF AGCLIGAEHWDTSYECDI GETALALLLIDRINO GETALALLLIDRINO GETALALLIDRINO GETALALLIDRINO

IPIGAGICASYHTVSLI SWFITORNFFSPQII FIAGLIAV

VVFLHVTYV KLPDDFMGCV VLNDLSRL

RENGLESKV

IGAIKLDOKDPOFKDNVI GETALALILL FLAWINLOFAYSNENE SNVVTGGIAIAMACIVGL PLRGTIVTRPLMESELVI YKLNTDHAGSNDNIALLV

NO AUTETISAPSLOV YISDAPSLOVSEKSGNFK VICHCKLIRIFERDISNVP RIFERDISNVPFSPDGK ITVEELKOLLEOWNLVIGFLFL LVIGAVIRGHLIRIMAGHPLGRCI

OPYVVDDPCPIHFYS PCPHFYSKWYRW

SKWYIRVGARKSAP GARKSAPLIELCVD

EAGSKSPIDYDIGN ICY/DIGN/TVSCLP

QVDVVNFNLT

GNYTVSCSPFTINCQ GNYTVSCLPFTINCQ

 March MARPHINS

 P10_2
 APPTING

 P10_3
 SLILCHMESHYMAQ

 P10_4
 NEIWAG/DOWNN

FSRQLONSV

SARS-CoV-2	Spike	QHD43416.1	
SARS-CoV-2	Spike	QHD43416.1	
SARS-CoV-1+SARS-CoV-2	Spike	QHD43416.1	
SARS-CoV-2	Spike	QHD43416.1	

	opixe	QRD43416.1	
	Spike	QHD43416.1	
1/-2	Spike	QHD43416.1	
N-2	Spike	QHD43416.1	
	Spike	QHD43416.1	
	Spike	QHD43416.1	
N-2	Spike	QHD43416.1	
1/-2	Spike	QHD43416.1	_
1/-2	Spike	QHD43416.1	
N-2	Spike	QHD43416.1	
1/-2	Spike	QHD43416.1	_
1/-2	Spike	QHD43416.1	
N-2	Spike	QHD43416.1	
	Spike	QHD43416.1	_
	Spike	QHD43416.1	
	Spike	QHD43416.1	_
	Spike	QHD43416.1	
	Spike	QHD43416.1	
	Spike	QHD43416.1	_
N-2	Spike	QHD43416.1	
N-2	Spike	QHD43416.1	_
N-2	Spike	QHD43416.1	_
N-2	Spike	QHD43416.1	
N-2	Spike	QHD43416.1	_
	Spike	QHD43416.1	_
	Spike	QHD43416.1	
	Spike	QHD43416.1	_
11-2	Spike	QHD43416.1	
	Nucleocapaid	QHD43423.2	
	Nucleocapaid	QHD43423.2	
	Nucleocanaid	 OHD43423.2	

	8488.CM/.2	Snike		OHD43416.1
	PARE CAUSARABE CAUS	Failer		CHEMINE 1
-	PARE CALL PARE CALLS	Peter		CHD43416.1
-	PARE CALL PARE CALLS	Peter		CHD43416.1
-	PARE CONTACEARE CONTA	Failer		CHEMINE 1
-	PARE CALL PARE CALLS	Peter		CHD43416.1
	\$48\$ CH/ 3	Failer		CHEMINE 1
	EABE CHU 3	Failer		CHEMINE 1
-	2488 Cold 3	Peter		CHD43416.1
-	PARE COLLARABE COLLA	Spice		CHEMISTRE 1
	\$10\$ C#/ 3	Musicement		04043433.3
	SARS-Colv-2	Nucleocapaid		OHD43423.2
	EABE CHU 2	Nucleocapaid		04043433.3
	PARE Cold 1 + PARE Cold 2 Municipal	TRACE COLORING		04043433.3
-	SARSCAV.2	Nucleocanaid		OHD43423.2
	2482 04/3	Musicement		04043433.3
	SARS-Criv-2	Nucleocapaid		OHD43423.2
	S485-CriV-2	Nucleocanaid		OHD43423.2
	S405-CvV-2	Nucleocanaid		OHD43423.2
	SARS_ColumnsARS_Column	biene		OHD43423.2
	SARS-CoV-2	Nucleocapaid		QHD43423.2
	SARS_Coll_1+SARS_Coll_2 Nucleon	him		OHD43423.2
	8488-Cr/V-2	Nucleocanaid		OHD43423.2
	SARS-CoV-2	Nucleocapaid		QHD43423.2
	SARS-CdV-2	Nucleocapaid		QHD43423.2
	SARS-CoV-2	Nucleocapsid		QHD43423.2
	SARS-CoV-1 +SARS-CoV-2 Nucleon	bird		QHD43423.2
	SARS-CoV-2	Nucleocapsid		QHD43423.2
	SARS-CoV-1 +SARS-CoV-2 Nucleon	apaid		QHD43423.2
I	SARS-CoV-2	Nucleocapaid		QHD43423.2
	PARE CONTACTOR CONTACT	bitter		00100100100
	Second and a second second	a subscription of the subs		Q11D43423.2
-	SARS-CoV-1+SARS-CoV-2 Nucleon	apaid		QHD43423.2
	SARS-CoV-1 +SARS-CoV-2 Nucleon SARS-CoV-2	apaid Nucleocapaid		QHD43423.2 QHD43423.2 QHD43423.2
	SARS-CoV-1+SARS-CoV-2 Nucleon SARS-CoV-2 SARS-CoV-2 SARS-CoV-2	apaid Nucleocapaid Nucleocapaid		QHD43423.2 QHD43423.2 QHD43423.2 QHD43423.2
	SARS-CoV-1 +SARS-CoV-2 Nucleon SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 Nucleon	apsid Nucleocapsid Nucleocapsid apsid		QHD43423.2 QHD43423.2 QHD43423.2 QHD43423.2 QHD43423.2
	SARS-CoV-1 + SARS-CoV-2 Nucleor SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 Nucleor SARS-CoV-2 Nucleor	apaid Nucleocapaid Nucleocapaid apaid Nucleocapaid		QHD43423.2 QHD43423.2 QHD43423.2 QHD43423.2 QHD43423.2 QHD43423.2
	SARS-Col/-1+SARS-Col/-2 Nucleon SARS-Col/-2 SARS-Col/-2 SARS-Col/-2 SARS-Col/-2 SARS-Col/-2 SARS-Col/-2 SARS-Col/-2	apaid Nucleocapaid Audeocapaid apaid Nucleocapaid Nucleocapaid		0H0434232 0H0434232 0H0434232 0H0434232 0H0434232 0H0434232 0H0434232
	SARS-Colv-1 + SARS-Colv-2 - Nucleoc SARS-Colv-2 SARS-Colv-2 SARS-Colv-2 - Nucleoc SARS-Colv-2 SARS-Colv-2 SARS-Colv-2	npaid Nucleocapaid Nucleocapaid apaid Nucleocapaid Nucleocapaid Nucleocapaid		0H0434232 0H0434232 0H0434232 0H0434232 0H0434232 0H0434232 0H0434232 0H0434232
	SARS-CoV-1 SARS-CoV-2 Nucleor SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 Nucleor SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 SARS-CoV-2	apaki Nucleocapaid Nucleocapaid apaki Nucleocapaid Nucleocapaid Membrane		0H0434232 0H0434232 0H0434232 0H0434232 0H0434232 0H0434232 0H0434232 0H0434232 0H0434232
	SARS Colv11 SARS Colv2 Nucleor SARS Colv2 SARS Colv2	apald Nucleocapaid Nucleocapaid apald Nucleocapaid Nucleocapaid Membrane Membrane		0H0434232 0H034232 0H034232 0H034232 0H034232 0H034232 0H034232 0H034232 0H034232 0H034232
	SNE CV/11 SAECV/2 Notice SAECV/2 SAECV/2 SAECV/2 SAECV/2 SAECV/2 SAECV/2 SAECV/2 SAECV/2 SAECV/2 SAECV/2 SAECV/2 SAECV/2 SAECV/2	Anto apaid Nucleocapaid Nucleocapaid Nucleocapaid Nucleocapaid Membrane Membrane		0H034232 0H034232 0H034232 0H034232 0H034232 0H034232 0H034232 0H034232 0H034232 0H034232 0H034232 0H034232
	SALE CALL SALE CALL INSIDE SALE CALLS SALE CALLS	paid Nacieccapsid Nacieccapsid Nacieccapsid Nacieccapsid Nacieccapsid Membrane Membrane Membrane Membrane		0H0434232 0H0434232 0H0434232 0H0434232 0H0434232 0H0434232 0H0434232 0H0434232 0H0434232 0H0434232 0H043419.1 0H043419.1
	SARE-CAV-1 FARE-CAV-2 Nucleon SARE-CAV-2 SARE-CAV-2 SARE-CAV-2 SARE-CAV-2 SARE-CAV-2 SARE-CAV-2 SARE-CAV-2 SARE-CAV-2 SARE-CAV-2 SARE-CAV-2 SARE-CAV-2 SARE-CAV-2 SARE-CAV-2 SARE-CAV-2	paid Nucleocapsid Nucleocapsid Nucleocapsid Nucleocapsid Nucleocapsid Membrane Membrane Membrane Membrane Membrane Membrane		0H05432 0H05432 0H05432 0H05422 0H05422 0H05422 0H05422 0H05422 0H05422 0H05422 0H05422 0H05422 0H054121 0H054121 0H054121
	SARE-Conv1 + SARE-Conv2 = Nucleon SARE-Conv2 = SarE-Conv2 = SarE-Conv2 = SARE-Conv2 = SARE-Conv2 = SARE-Conv2 = SARE-Conv2 = SARE-Conv2 = SARE-Conv2 = SARE-Conv2 = SARE-Conv2 = SARE-Conv2 = SARE-Conv2 = SARE-CONC2 = SARE-CONC2 = SARE-CONC2 = SARE-CONC2 = SARE-CONC2 = SARE-CONC2	paid paid Nucleocapaid Nucleocapaid Nucleocapaid Nucleocapaid Membrane Membrane Membrane Membrane Membrane Membrane		0H054832 0H054832 0H054832 0H054832 0H054832 0H054832 0H054832 0H054832 0H054832 0H054831 0H054831 0H054831 0H0548181 0H0548181 0H0548181
	SARE-GW1 SARE-GW2 Nucleo SARE-GW2 SARE-GW2 SARE-GW2 SARE-GW2 SARE-GW2 SARE-GW2 SARE-GW2 SARE-GW2 SARE-GW2 SARE-GW2 SARE-GW2 SARE-GW2 SARE-GW2 SARE-GW2 SARE-GW2	pand pand Naclescapsid paid paid Naclescapsid Naclescapsid Membrane Membrane Membrane Membrane Membrane Membrane Membrane		0HD3432 0HD3432 0HD3432 0HD3432 0HD3432 0HD3432 0HD3432 0HD3432 0HD3432 0HD3432 0HD3432 0HD3432 0HD3412 0HD3412 0HD3412 0HD3412 0HD3412 0HD3412
	SARE-CW1 SARE-CW2 Nation SARE-CW1 SARE-CW2 SARE-CW12 SARE-CW12 SARE-CW12 SARE-CW2 SARE-CW2 SARE-CW2 SARE-CW2 SARE-CW2 SARE-CW1	And Nucleocapsid And Second Nucleocapsid Nucleocapsid Nucleocapsid Nucleocapsid Nucleocapsid Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane		0H05432 0H05432 0H05432 0H05432 0H05432 0H05432 0H05432 0H05432 0H05412 0H05412 0H05412 0H05412 0H05412 0H05412 0H05412 0H05412 0H05412
	SARE-CAV1 SARE-CAV2 Nation SARE-CAV2	Apart Anticessant Nucleocapaid apart Nucleocapaid Nucleocapaid Nucleocapaid Nucleocapaid Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane	Politification	0H054032 0H053632 0H053632 0H053632 0H053632 0H053632 0H053632 0H053632 0H053632 0H053622 0H053622 0H053623 0H053623 0H0536151 0H0536151 0H0536151 0H0536151 0H0536151 0H0536151
	SARE CAVL SEARE CAVL States SARE CAVL SARE CAVL	parist parist parist parist Nucleocapatid parist Nucleocapatid Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Spite	Postar galari Website galari Website Televite	01034132 01034132 01034132 01034132 01034132 01034132 01034132 01034132 01034132 01034131 01034151 01034151 01034151 01034151 01034151 01034151 01034151 01034151
	SAME CAV1 SAME CAV2 Nation SAME CAV2 SAME CAV	para para Nucleocapsid Nucleocapsid Nucleocapsid Nucleocapsid Membrans Membrans Membrans Membrans Membrans Membrans Membrans Membrans Membrans Membrans Membrans Spid Cft73a Spide Spide	FORFITSELOS FORFITSELOS ASSERVICTOS	01003433 011034033 011034033 011034033 011034032 011034032 011034032 011034032 011034032 011034032 011034032 011034031 011034051 011034051 011034051 011034051 011034051 011034051 011034051 011034051 011034051
	SARE-CAYL 1638/E-CAYL 1638/E SARE-CAYL	April Constant Nucleocapsid Nucleocapsid Nucleocapsid Nucleocapsid Membrane Membrane Membrane Membrane Membrane Membrane Membrane Spite Spite Spite Spite Spite	F03659798.107 WWW181998.207 WW181998.207 S940441105100	0 PID34232 0 PID34161 0 PID34161
	SUPECIV11438EC4V2 Nume SMACVA SAMSCVA SMACVA	paris Bartenansid Nucleocapsid Javis Nucleocapsid Nucleocapsid Mentoras Mentoras Mentoras Mentoras Mentoras Mentoras Spite Spite Spite Spite	N001100.001 N00110.001 ACLARMANTICS ACLARMANTICS OPERATION	010342.3 010342.3 010342.3 010342.3 010342.3 010342.3 010342.3 010342.3 010342.3 010342.3 010342.3 010342.3 010341.1 010341.1 010341.1 010341.1 010341.1 010341.1 010341.1
	SUPECIV1 SUPECIV1 SUPECIV1 SUPECIV1 SUPECIV1	Autorianaid Nucleocopid aptid Nucleocopid Nucleocopid Nucleocopid Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Spis Spis Spis Spis Spis	POSID POSICOV Design of the same constant the same constant to the same constant to the same constant to the same the same constant to the same constant the same constant to the same constant to the the same constant to the same constant to the the same constant to the same constant to the same constant to the same constant to the same constant to the same constant to the same constant to the same constant to the same constant to the the same constant to the same	OPD3425 OPD342 OPD342 OPD342 OPD341 OPD34 O
	SHE SUP 1 ARRE CV1 SHE SUP 1 ARRE CV1 SHE SUP 1 ARRE CV1 SHE SUP 1 ARRE CV12 SHE SUP 1 ARRE CV12 SHE SUP 1 ARRE CV12 SHE SUP 1 ARRE CV12 SHE SUP 1 ARRE CV12 SHE SUP 1 ARRE CV12 SHE SUP 1 ARRE CV12 SHE SUP 1 ARRE CV12 SHE SUP 1 ARRE CV12 SHE SUP 1 ARRE CV12 SHE SUP 1 ARRE CV12 SHE SUP 1 ARRE CV13 SHE SUP 1 ARRE CV12 SHE SUP 1 ARRE CV14 SHE SUP 1 ARRE CV14 SHE SUP 1 ARRE CV14 SHE SUP 1 ARRE CV14 SHE SUP 1 ARRE CV14 SHE SUP 1 ARRE CV14 SHE SUP 1 ARRE CV14 SHE SUP 1 ARRE CV14 SHE SUP 1 ARRE CV14 SHE SUP 1 ARRE CV14	Auto Autocompaid Nucleocopaid Autocompaid Nucleocopaid Nucleocopaid Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Spike Spike Spike Spike Spike Spike Spike	FOREFORENCY WYCH PRODUCT OWNALLING O	0 (PD5462) 0 (PD5
	5015-0211-0305-0271-0305-0271 5015-0211-0305-0212 5015-0211-0305-0212 5015-0211-0305-0212 5015-021-0305-0212 5015-0212 5015-0212 5015-0212 5015-0212 5015-0211 5015-02	Active Marineconsid Nucleocoped pati Nucleocoped Nucleocoped Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Mentrans Spit Citis Spit Spit Spit Spit Spit Spit Spit Spit	Fool.0704.007 Fool.0704.007 AXX5404000000 Cost.0011000 Wina 2000.0000 Wina 2000.0000 Wina 2000.0000 Wina 2000.0000	OPD34263 OPD34263 OPD34263 OPD3423 OPD3423 OPD3423 OPD3423 OPD3423 OPD3423 OPD3423 OPD3423 OPD3423 OPD342 OPD341 OPD34
	SUPECICI 1488E CV/2 1488E SUPECIC/2 1488E SUPECIC	Autor Autorianopaid Nucleorapaid Nucleorapaid Nucleorapaid Nucleorapaid Nucleorapaid Nucleorapaid Nucleorapaid Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Spite Spite Spite Spite Spite	Postbirtisk.dor More Statistics 2000 - Statistic	GPD3423 GPD3419 GPD341 GPD34
	SPECIAL 14885 CV1 SPECIAL SPE	Autorisersamid Nucleocapsid Nucleocapsid Nucleocapsid Nucleocapsid Nucleocapsid Nucleocapsid Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Membrane Spile Spile Spile Spile Spile Spile	Popular Par. NV Popular Par. NV Popular Par. Par. Par. Par. Par. Par. Par. Pa	OPD34232 OPD34232 OPD34232 OPD3432 OPD3432 OPD34232 OPD34232 OPD34232 OPD34232 OPD34232 OPD3423 OPD3423 OPD3423 OPD3423 OPD341 OPD34
	5015-0011-0305-0071-0305-0071 5015-0071-0305-0072 5015-0071-0005-0072 5015-0071-0005-0072 5015-0071-0005-0072	Austinopanid Nucleocapanid Nucleocapanid Nucleocapanid Nucleocapanid Nucleocapanid Nucleocapanid Nucleocapanid Membrane Membrane Membrane Membrane Membrane Membrane Spike Spike Spike Spike Spike Spike Spike Spike Spike	FOOLPFORTON BY THE STATE OF THE	dPDS4632 dPDS4632 dPDS4632 dPDS4632 dPDS4632 dPDS4632 dPDS4632 dPDS4632 dPDS4632 dPDS463 dPDS46 d
	SPECIPIC 1488 CM2 Nonexit	Nationani Nation	NOT ON ON WAS IN PERFO ALCOUNT ON DESCRIPTION DESCRIPTION DESCRIPTION DESCRIPTION LIPPOT	GPD34232 GPD34232 GPD34232 GPD34232 GPD34232 GPD34232 GPD34232 GPD34232 GPD3423 GPD34161 GPD3416 GPD341 GPD3 GPD341 GPD3 GPD34 GPD3 GPD34 G
	Selection 1 (Selection) Tester (Selection) Tester (Selection) Selection 1 (Selection) Selection 1 (Selection) Tester (Selection)	and Andreaming Nachacapaid agust Nachacapaid Machacapaid Nachacapa	POINTSOLOGY Montant Integrate Social Antigoto Social Antigoto Social Antigoto Market Social Market S	drob4032 drob403 drob403 drob403 drob403 drob403 drob403 drob403 drob403 drob403 drob40 dr
	State Cont Laboration Cont Laboration Cont	Anise Aniseconsel Naciocopati april Naciocopati Anisecopati Naciocopati Naciocopati Naciocopati Naciocopati Naciocopati Naciocopati Naciocopati Naciocopati Naciocopati Naciocopati Naciocopati Naciocopati Naciocopati Naciocopati Naciocopati Naciocopati Naciocopati Spis Spis Spis Spis Spis Spis Spis Spi	Polytyper.com Po	dPDS4632 dPDS4632 dPDS4632 dPDS4632 dPDS4532 dPDS4531 dPDS4531 dPDS4531 dPDS4531 dPDS4531 dPDS453 dPDS453 dPDS453 dPDS453 dPDS45

AGULGAENVINGTEUDI
GDAALALLLLDRLNQ
GHLRIAGHHLGRCDI
NFNGLTGTGVLTESNOCF
DIPIGAGICASYOTOTNS
HWFVTORNFYEPOIL
LPDPSKPS
KLPDDF1GCV
RLNQLESKM
WLTY GAIKLODKOPN
NFKDQVILLNKHIDAYK
MAGNGGDAALALLLLDRLNQLESKM
TWLTYTGAIKLODKDPNFKDQVILL
GDAALALLLL
LVIGFLFLTWICLLOFAYANRNRF
VLAAVYRINWITGGIAIAMACLVGLMW
ILLNVPLHGTILTRPLLESELVIG
IGNYKLNTDHS8SSDNIALLV
GHLRIAGHHLGRCDI
PIQASLPFGWLIVGV
DVNCTEVPVAHADQLTPTWR
KDKKKKADETQALPQRQKKQ
QRQKKQQTVTLLPAADLDDF5KQ

MAD INGTITVEELIKKLEOWINLVIGFLFLTW

ANNAATVLOLPOGTTLPKGPYAEGSR KKADE TOALPOROKKOOTVTLLPAADLDDFSKOLOOSM

psid Nucleocapsid psid

ucleocapsid

Nucleocapsid

Nucleocapaid Nucleocapaid

Membrane Membrane Membrane Membrane Of073a Solke Solke Solke Solke Solke Solke Solke Solke Solke Membrane Membrane

Nucleocapaid Nucleocapaid KIT ORF8 ORF8 ORF8 ORF8 ORF8 ORF8

Criva
 C

SARS-CoV-SARS-CoV-

SARS-C

SARS-C

SARS-CoV-2



QHD43422.1 QHD43422.1 QHD43422.1

QHD43422.1 QHD43422.1 QHD43422.1

0HD434221 0HD434221 0HD434221 0HD434221 0HD434221 0HD434221 0HD434221 0HD434221

0H043422.1 0H043422.1 0H043422.1 0H42122.1 0H42122.1 0H42122.1 0H42122.1 0H42122.1

QHH2122.1

QHN73801.1 QHD43422.1 QHD43417.1







44941047 AAP41047.1 AAP41047.1 AAP41047.1 AAP41047.1 AAP41047.1 AYV29776.1 AAP41037.1 AAP41037.1 AAP41047. AAP41041. AAP41037. AAP41037.1 AAP41037.1 AAP41037.1 AAP41037.1 AAP41037.1 AAP41037.1 AAP41037.1 AAP41037. AAP41037. AAP41037. AAP41047.1 AAP41047.1 AAP41047.1 AAP41047. AAP41047. AAP41047. AAP41047.1 AAP41047.1 AAP41047.1 AAP41041.1 AAP41041.1 AAP41041.1 AAP41041.1

AAP41033

AAP41037.1 AAP41037.1

AAP41037.1 AAP41037.1 AAP41037.1 AAP41037.1 AAP41037.1 AAP41037.1 AAP41037.1

AAP41037.1 AAP41037.1 AAP41037.1 AAP41037.1 AAP41037.1

AAP41037

AAP41047.

AAP41047.1 AAP41047.1

258

1123

272

302

AAP41041.1 AYV99775.1 AYV99775.1 AYV99775.1 AAP41047.1 AAP41047.1 AAP41047.1 AAP41037. AAP41037. AAP41037. AAP41037. AAP41041. AAP41041. AAP41047 AAP41047



SARS-CoV-1 last position

972

1152

288

316

Table S8a. HLA phenotyping and genotyping of susceptible and resistant individuals (class I).

		HL	_A-A	alle	les																																		
	Allele freq.(%)	25.8	11.7	9.5	8.53	7.36	3.73	3.52	2.99	2.77	2.03	2.03	2.03	1.71	1.6	1.39	1.39	1.39	v	<1	٧	v	4	2	۲ V		5	v	4	2	v	<1	v	۲	<1	٢	v	<1	v
Peptide sequence	Mutated and WT peptide name	HLA-A02:01	HLA-A03:01	HLA-A01:01	HLA-A24:02	HLA-A11:01	HLA-A26:01	HLA-A23:01	HLA-A29:02	HLA-A32:01	HLA-A68:01	HLA-A25:01	HLA-A68:02	HLA-A02:05	HLA-A31:01	HLA-A30:01	HLA-A30:02	HLA-A33:01	HLA-A29:01	HLA-A02:02	HLA-A33:03	HLA-A01:02	HLA-A01:03	HLA-A02:03	HLA-A02:06	HLA-AUZ:U/	HLA-A02:08	HLA-A02:11	HLA-A03:02	HLA-A24:03	HLA-A26:08	HLA-A30:04	HLA-A34:02	HLA-A36:01	HLA-A66:01	HLA-A66:02	HLA-A69:01	HLA-A74:01	HLA-A74:03
RFASVYAWNRKRISN	Spike24wt	0	1	0	1	2	0	1	0	1	2	0	0	0	2	1	0	2	0	0	2	0	0	0	0	0	0	0	1	1	0	0	2	0	2	2	0	2	2
CVADYSVLYNSASFS CVADYSFLYNSASFS	Spike25wt Spike25_V367F	0	1	2	1	1	2 2	1	2 2	2 2	1	2	0	0	0	0	2 2	0	2 2	0	0	2 2	2	0 2	0	0 0	0	0 1	1	1	2 2	2 2	2 2	2 2	2 2	2 2	0	0	0
TFKCYGVSPTKLNDL	Spike26wt	0	1	0	1	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0	0	1	1
CFTNVYADSFVIRGD	Spike27wt	0	0	2	2	1	1	2	1	1	2	2	2	2	1	0	0	2	1	1	2	1	2	1	1	1	2	1	1	1	2	1	2	1	2	2	2	1.	1
EVRQIAPGQTGKIAD EVRQIAPGQTGNIAD	Spike28wt Spike28_K417N	0	0	0	0	1	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0 0	0	0	2	0	0	0	2	0	1	1	0	1	1
EVRQIAPGQTGPIAD	Spike28_K417P	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	0	0	1	1	0	0	0
YNYKLPDDFTGCVIA	Spike29wt	1	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	2	0	0	0	2	2	2	2	1	0	0	0	0	0	0	0	0	0	0	0
WNSNNLDSKVGGNYN WNSKNLDSKVGGNYN WNSNKLDSKVGGNYN	Spike30wt Spike30_N439K Spike30_N440K	0	0	2 2 2	0 0 0	1 1 2	0 0 0	0 0 0	0 0 0	0 0	2 2	2 2 2	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	000000000000000000000000000000000000000	1 1 0	0	0000	2 2 2 2	0 0 0	0 0 0	0 0 0	0 0 0	0000											
YLYRLFRKSNLKPFE YRYRLFRKSNLKPFE	Spike31wt Spike31_L452R	0	2 2	0	1	2 2	0	1	0	2	1	0	0	0	2 2	2 2	0 0	0	0	0	0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	2 2	1 1	0 0	1	2 2	0 0	0 0	0	0	2	2 2
RDISTEIYQVGSTPC RDISTEIYQAGSTPC	Spike32_A475V Spike32wt	0	0	0	0	0	0	0	0 0	0 0	0	0 0	1	0	0	0	0 0	0	0	0	0	0	0	0	0		0	0	0	0	0 0	0	0	0 0	0	0 0	2	0	0
RDISTEIYQAGNTPC RDISTEIYQAGSKPC	Spike32_S477N Spike32_T478K	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	2	0	0	0
NGVEGENCYEPLQSY	Spike33_E484K	0	0	1	1	0	1	1	2	2	0	1	0	0	1	1	1	0	2	0	0	2	1	0	1	1	0	0	0	1	1	1	0	1	0	0	0	1	1
NGVQGFNCYFPLQSY NGVEGFNCYFPLRSY NGAEGENCYFPLOSY	Spike33_Q493R Spike33_V483A	0	0	1	0	0	1	0	2 2 2	0	2	0	1	0	2	0	1	2	2 2 2	0	2	2 2 2	1	0	0	0	0	0	0		1	1	1	1	0	0	1	1	1
GFQPTNGVGYQPYRV GFQPTYGVGYQPYRV	Spike34wt Spike34 N501Y	0	0	1	0	0	1	0	1	0	1	0	0	0	0	0	2	1	1 2	0	1 2	2	1	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	0
VAU SEELL HARATVC	Spike35wt	2	1	0	0	1	0	0	- 1	0	0	0	1	- 1	0	0	0	0	4	2	0	0	0	2	2	2	1	2	0	0	0	0	0	0	0	0	2	0	0

-	_		
0	0	LEGEND:	
1	1	0 = no binding	
1	1	1 = weak binding(contains at	leastone8-11mer weak binder)
1	1	2 = strong binding(contains a	atleastone8-11mer strongbinder)
1	1		

		HL/	A-Ва	lleles				_																																				_	_	_	_	_		<u></u>	_	_	
	Allele freq.(%)	11.43	7.48	6.73	5.98	5.24	4.81	4.4 v 3.95	2.35	2.35	2.14	2.03	2.03	1.92	1.71	1.6	1.39	1.18	1.18	1.07	v	÷ 5	2	v	v v	v	5	5	<1	2	- -	2	7 5	2	7	7 5	v	2 2	v	4	5 5	ŕ,	۲.	v v	÷ 5	2	5	⊽ v	v	2	2 2	v v	2
Peptide sequence	Mutated and WT peptide name	HLA-B07:02	HLA-B08:01	HLA-B18:01 HLA-B44:02	HLA-B51:01	HLA-B35:01	HLA-B44:03	HLA-B14:02	HLA-B13:02	HLA-B27:05	HLA-B38:01 HLA-B49:01	HLA-B35:03	HLA-B40:02	HLA-B40:01 HLA-B57:01	HLA-B50:01	HLA-B55:01	HLA-B14:01 HLA-B35:02	HLA-B53:01	HLA-B37:01	HLA-B52:01 HLA-B58:01	HLA-B35:08	HLA-B15:02 HI A-B15:03	HLA-B15:10	HLA-B15:17	HLA-B27:02 HLA-B27:03	HLA-B46:01	HLA-B56:01	HLA-B5/:03 HLA-B39:01	HLA-B40:06	HLA-B41:01	HLA-B42:01 HLA-B45:01	HLA-B07:05	HLA-B0/ :00	HLA-B15:16	HLA-B15:18	HLA-B10:03	HLA-B27:05	HLA-B35:04 HLA-B35:05	HLA-B35:43	HLA-B39:10	HLA-B41:02 HLA-B44:05	HLA-B47:01	HLA-B50:02	HLA-B51:02 HLA-B58:02	HLA-B78:01	HLA-B81:01	HLA-B38:02	HLA-B39:00 HLA-B39:24	HLA-B40:16	HLA-B44:04	HLA-B51:08	HLA-Bot.v.	HI A.B82-01
RFASVYAWNRKRISN	Spike24wt	0	1	0 0	1	0	0	0 0	0	0	0 0	0	0	0 1	0	0	0 0	0	0	0 1	0	0 0	0 (0	1 0	0	0	0 0	0	0	0 0	0	0 (0	0 (0 0	0	0 0	0	0	0 0	0	0	1 1	0	0	0 0	0 0	0	0	1 (0 0	(
CVADYSVLYNSASFS CVADYSFLYNSASFS	Spike25wt Spike25_V367F	0	0	0 0	0	2 2	0	2 1	0	0	0 0 0 0	1	0	0 1 0 1	1	0	0 1 1 1	1	1	1 1 2 2	2 2	2 2	0	2 2	0 0	2 2	0	2 0 2 0	1	1	0 1 0 1	0	0 1 0 1	2 2	1 (0 0	0	1	2 2	0	0 0 0 0	0	1	0 1	0	0	0 0	0 0	0	0	0 0) (1
TFKCYGVSPTKLNDL	Spike26wt	1	0	0 0	0	0	0	9 0	0	0	0 0	0	0	0 0	0	0	0 0	0	0	0 0	0	0 0	0 (0	0 0	0	0	0 0	0	0	1 0	1	1 0	0	0 (0 0	0	0 0	0	0	0 0	0	0	0 0	0	0	0 (0 1	0	0	0 0	0 C	(
CFTNVYADSFVIRGD	Spike27wt	0	0	0 0	1	2	0	1 1	2	0	1 0	1	0	0 0	0	0	1 1	1	0	2 1	2	1 1	1	2	0 0	2	0	1 1	0	0	0 0	0	0 1	2	1 (0 0	0	1 2	2	1	0 0	0	0	1 1	1.	0	0	1 1	0	0	1 (0 C	
EVRQIAPGQTGKIAD EVRQIAPGQTGNIAD EVRQIAPGQTGPIAD	Spike28wt Spike28_K417N Spike28 K417P	1	0		1	0	0		2 2 2	1	0 1 0 1	0	0	0 0	1	1		0	0	1 0 2 0	0	0 1	0	0	0 1	0	1	0 0	0	0	1 0 1 0	1	1 2 1 2	0	0 0		1		0	0	0 0	1	0	1 0		0	0 0	0 0	1	0	0 0) 0 1 (1
VNYKI PDDETGCVIA	Spike29wt	1	0	0 0	2	1	0	0 0	0	0	0 0	2	0	0 0	0	1	1 2	2	0	0 0	2	0 0	0	0	0 0	0	2	0 0	0	0	1 0	1	1 0	0	0	1 0	0	2 0	0	2	0 0	0	0	2 0	1	1	0	0 0	0	0	2	5 6	
WNSNNLDSKVGGNYN WNSKNLDSKVGGNYN WNSNKLDSKVGGNYN	Spike30wt Spike30_N439K Spike30_N440K	0	0 0 0		0 0 0	0 0 0	0	0 0	0	0		0 0 0	0 0 0		0	0	0 0 0 0 0 0	0 0 0	0 0		0 0	1 0		0	0 0 0 0 0		0 0 0		0	0		0		0			0 0 0		0	0 0 0		0	0 0			0			0	0 0) 0 0 (
YLYRLFRKSNLKPFE YRYRLFRKSNLKPFE	Spike31wt Spike31_L452R	0	2 2	0 0	0	0	0	1 2 1 2	0	2 2	0 0	0	0 0	0 0 0 0	0	0	2 0 2 0	0	0	0 0 0 0	0	1 1	1	0	1 2 2 2	0	0 0	0 1 0 1	0	0	0 0 0 0	0	0 1 0 1	0	2 2) 2) 2	2 2	0 0	0	0 0	0 0	0	0	0 0	0	0	1 (0 2 0 2	0 0	0 0	0 0) 1 0	
RDISTEIYQVGSTPC RDISTEIYQAGSTPC RDISTEIYQAGNTPC	Spike32_A475V Spike32wt Spike32_S477N	0	0	1 0 0 0 0 0	0	0	0	0 0	1	0	0 1 0 1 0 1	0	1 0 0		2 2 2	0		0	1 0 0		0			0 0 0	0 0 0 0 0 0 0		0		1	1	0 1 0 1 0 1	0		0	0 0		0 0		0	0	0 0 0 0 0 0 0	0	2 2 2	0 0 0 0 0 0	0	0		0 0	0	0	1 0		
NGVEGENCYEPLQSY NGVKGENCYEPLQSY	Spike32_1476K Spike33wt Spike33 E484K	0	1	1 1	1	1	1		0	0	0 1 0 0	1	2	2 0 0 0	1	0	1 1 0 0	0	2	1 0 2 1	1	2 1	0	0	0 0	1	0	0 1	2	1 0		0		0	0	1 0 1 0	0	1 1	1	1	2 2 0 0	2	1	1 0	1	1	0) 0 1 1 0 1	2	1	1 0		T
NGVQGFNCYFPLQSY NGVEGFNCYFPLRSY	Spike33_E484Q Spike33_Q493R	0	0	0 0	0	1	0	1 1	2	0	1 0 0 1	1	1	1 0 2 0	0	0	1 1	0	1	2 0 1 0	1	2 1 1 1	0	0	0 0	1	0	0 1	0	0	0 0	0	2 0 1	0	0	1 1	0	1 1	1	1	0 0	2	0	0 1	1	1	1	1 1	0	0	0 0	0 0	
GFQPTNGVGYQPYRV GFQPTYGVGYQPYRV	Spike33_V483A Spike34wt Spike34_N501Y	0	0	1 0 0 0	0	1	0	1 0	0	0	0 0 0	0	0 0	2 0 0 0 0 0	0	0	1 1 0 0 0 0	0	0	1 0 1 0 1 0	1	2 1 1 1 1 2	0	0	0 0	1	0	0 0 0	0	0	0 0 0 0	0) 2) 0) 0	0	2 2		0	1 1 0 1 0 1	1	0	2 2 0 0 0 0	0	0	1 0 0 0 0 C		0	0 (0	0) 0) 0 1 (
W// SEELLUADATVC	Spike35wt	0	0	2 0	0	0	0	0 0	1	0	2	0	2	1 0	2	4	0 0	0	2	1 0	0	0.0	0	0	0 0	0	1	0 0	2	2	2	0	1	0	0	0	0	0 0	0	0	2 1	- 1	2	0 0	1	0	0	1 0	1	0	0 1	1 1	1

		HL	A-C	allel	les		_		_																_				_		_	
	Allele freq.(%)	14.16	12.23	12.02	7.94	7.4	5.47	5.47	5.04	4.51	4.08	4.08	3.33	2.9	1.61	1.5	<1	4	v	۲,	v	v	v	v	v	ř	v	v	v	v	v	v
Peptide sequence	Mutated and WT peptide name	HLA-C07:01	HLA-C07:02	HLA-C04:01	HLA-C06:02	HLA-C05:01	HLA-C12:03	HLA-C02:02	HLA-C08:02	HLA-C16:01	HLA-C03:03	HLA-C03:04	HLA-C01:02	HLA-C15:02	HLA-C14:02	HLA-C12:02	HLA-C02:10	HLA-C03:02	HLA-C07:04	HLA-C08:01	HLA-C17:01	HLA-C04:03	HLA-C07:18	HLA-C08:04	HLA-C15:04	HLA-C15:05	HLA-C15:06	HLA-C15:09	HLA-C16:02	HLA-C16:04	HLA-C17:03	HLA-C18:01
RFASVYAWNRKRISN	Spike24wt	0	1	0	1.	0	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
CVADYSVLYNSASFS CVADYSFLYNSASFS	Spike25wt Spike25_V367F	1	1	0	0	1	1	2	1	2 2	2 2	2 2	1	0	1	2 2	2 2	2 2	0	1	1	1	1	1	2 2	1	1	2 2	1	2 2	1	0
TFKCYGVSPTKLNDL	Spike26wt	0	1	0	0	0	0	0	0	0	0	0	2	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
CFTNVYADSFVIRGD	Spike27wt	1	1	1	0	1	2	2	1	2	2	2	0	1	1	2	2	2	1	2	1	2	1	2	2	1	1	2	2	2	1	1
EVRQIAPGQTGKIAD	Spike28wt	0	0	0	0	0	1	0	0	0	0	0	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0
EVRQIAPGQTGNIAD	Spike28_K417N	0	0	0	1	0	1	0	0	0	0	0	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0
EVRQIAPGQTGPIAD	Spike28_K417P	0	0	0	0	0	1	0	0	1	1	1	2	0	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	1	1	0
YNYKLPDDFTGCVIA	Spike29wt	0	0	1	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	1
WNSNNLDSKVGGNYN	Spike30wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WNSKNLDSKVGGNYN	Spike30_N439K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WNSNKLDSKVGGNYN	Spike30_N440K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
YLYRLFRKSNLKPFE YRYRLFRKSNLKPFE	Spike31wt Spike31_L452R	2	2	0	2	0	1	0	0	0	0	0	0	0	1	1	0	0	2	0	0	0	2	0	0	0	0	0	0	0	0	1
RDISTEIYQVGSTPC	Spike32_A475V	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RDISTEIYQAGSTPC	Spike32wt	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RDISTEIYQAGNTPC	Spike32_S477N	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RDISTEIYQAGSKPC	Spike32_T478K	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NGVEGFNCYFPLQSY	Spike33wt	1	1	0	0	1	1	1	1	1	0	0	0	0	2	1	1	1	0	1	0	1	1	0	1	0	0	1	0	1	0	0
NGVKGFNCYFPLQSY	Spike33_E484K	1	1	1	0	0	1	1	0	1	0	0	1	1	2	1	1	1	0	1	1	0	1	1	1	0	0	1	1	1	1	0
NGVQGFNCYFPLQSY	Spike33_E484Q	1	1	1	0	0	1	1	0	1	1	1	0	0	2	1	1	1	0	1	0	0	1	1	1	0	0	1	0	1	0	0
NGVEGFNCYFPLRSY	Spike33_Q493R	1	1	0	0	1	1	1	1	1	0	0	0	0	2	1	1	1	0	1	0	1	1	0	1	0	0	1	0	1	0	0
NGAEGFNCYFPLQSY	Spike33_V483A	1	1	1	0	2	1	1	1	1	0	0	0	0	2	1	1	1	0	1	0	1	1	1	1	0	0	1	0	1	0	0
GFQPTNGVGYQPYRV	Spike34wt	0	2	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GFQPTYGVGYQPYRV	Spike34_N501Y	1	2	0	0	0	1	1	0	0	0	0	0	0	2	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0
VVLSFELLHAPATVC	Spike35wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Table S8b. HLA phenotyping and genotyping of susceptible and resistant individuals (class II).

		HL	A-DI	P all	eles										HL	A-DO	ם all	eles					
	Allele freq. (%)	34.32	13.11	11.44	8.23	6.43	F.O. 7	17.6	2.96	2.96	2.06	1.8	1.67	1.67		00.10	z 1.0U		1164	5	11.30	11.07	
Peptide sequence	Mutated and WT peptide name	DPA10103-DPB10401	DPA10103-DPB10201	DPA10103-DPB10402	DPA10103-DPB10301	DPA10201-DPB10101	DPA10202-DPB10501	DPA10201-DPB10501	DPA10201-DPB11701	DPA10201-DPB11301	DPA10201-DPB11101	DPA10201-DPB11001	DPA10201-DPB11401	DPA10103-DPB10601	DQA10501-DQB10301	DQA10505-DQB10301	DQA10301-DQB10301	DQA10401-DQB10301	DQA10101-DQB10501	DQA10102-DQB10501	DQA10102-DQB10602	DQA10201-DQB10202	DOA40501-DOB10201
RFASVYAWNRKRISN	Spike24wt	0	0	0	1	0	1	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	(
CVADYSVLYNSASFS	Spike25wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(
CVADYSFLYNSASFS	Spike25_V367F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(
TFKCYGVSPTKLNDL	Spike26wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(
CFTNVYADSFVIRGD	Spike27wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
EVRQIAPGQTGKIAD	Spike28wt	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	(
EVRQIAPGQTGNIAD	Spike28_K417N	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
EVRQIAPGQTGPIAD	Spike28_K417P	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	
YNYKLPDDFTGCVIA	Spike29wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(
WNSNNLDSKVGGNYN	Spike30wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(
WNSKNLDSKVGGNYN	Spike30_N439K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
WNSNKLDSKVGGNYN	Spike30_N440K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
YLYRLFRKSNLKPFE	Spike31wt	1	1	1	0	0	2	2	1	0	0	1	1	1	0	0	0	0	0	0	0	0	(
YRYRLFRKSNLKPFE	Spike31_L452R	1	1	1	0	0	2	2	1	0	1	1	1	1	0	0	0	0	0	0	0	0	
RDISTEIYQVGSTPC	Spike32_A475V	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(
RDISTEIYQAGSTPC	Spike32wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
RDISTEIYQAGNTPC	Spike32_S477N	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
RDISTEIYQAGSKPC	Spike32_T478K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGVEGFNCYFPLQSY	Spike33wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	(
NGVKGFNCYFPLQSY	Spike33_E484K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
NGVQGFNCYFPLQSY	Spike33_E484Q	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
NGVEGFNCYFPLRSY	Spike33_Q493R	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
NGAEGFNCYFPLQSY	Spike33_V483A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
GFQPTNGVGYQPYRV	Spike34wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(
GFQPTYGVGYQPYRV	Spike34_N501Y	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(
VVI SEELI HAPATVC	Spike35wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	(

HL/	A-DC) all	eles									_		_				
	01 BU	700.1 7		11 01	+0. 1	11.30	11.07	90.01	10.30	7.88	4.79	44	ŕ	3.08	2.51	2.40	0 C C	07.7
DQA10501-DQB10301	DQA10505-DQB10301	DQA10301-DQB10301	DQA10401-DQB10301	DQA10101-DQB10501	DQA10102-DQB10501	DQA10102-DQB10602	DQA10201-DQB10202	DQA10501-DQB10201	DQA10201-DQB10201	DQA10301-DQB10302	DQA10103-DQB10603	DQA10101-DQB10503	DQA10104-DQB10503	DQA10102-DQB10502	DQA10102-DQB10604	DQA10401-DQB10402	DQA10201-DQB10303	DQA10301-DQB10303
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	0	0	0
0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	0	0	0
0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0
0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
U	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	0	0	0

LEC	GEND :
0	= no binding
1	= weak binding
2	= strong binding

		HL	_A-D	DR al	lleles	;																																						
	Allele freq. (%)	12.58	10.89	9.83	8.46	6.24	5.71	5.29	4.65	4.55	3.17	2.33	1.9	1.9	1.9	1.8	1.8	1.7	1.48	1.48	1.37	1.06	1.06	v	v	v	v	V	⊽	⊽	v	⊽ '	, .	7	7 2	. 1	7 7	7 7	7 7	- u	5/11 0/12	e/ د	11/a	~ n/a
Peptide sequence	Mutated and WT peptide name	DRB1 0701	DRB1 1501	DRB1 0301	DRB1_1101	DRB1_0101	DRB1_0401	DRB1_1301	DRB1_1302	DRB1_1104	DRB1_0102	DRB1_0404	DRB1_0405	DRB1_1454	DRB1_1601	DRB1_0801	DRB1_1401	DRB1_1303	DRB1_1001	DRB1_1201	DRB1_1502	DRB1_0804	DRB1_0901	DRB1_0403	DRB1_1102	DRB1_0402	DRB1_1202	DRB1_1503	DRB1_0103	DRB1_0407	DRB1_1103	DRB1_0302	2001_187U	DKB1_0406	DRB1 1304	DB4 1305	UND1_107U	TOPE1_10408	UKB1_0400	DRB3 0101		UKD3_0404	10104_0101	DRB5 0202
RFASVYAWNRKRISN	Spike24wt	0	1	0	2	0	0	2	0	1	0	0	0	1	2	1	1	2	0	0	0	1	0	0	2	1	1	1	1	0	2	1	1	0	0 2	- 4	2 () (0 1	1 C) 1	1 (0	2
CVADYSVLYNSASFS	Spike25wt	0	C) ()	0	1	2	0	1	0	0	1	2	0	1	0	0	0	2	0	1	0	0	1	0	0	0	0	0	1	0	1	1	1) ()	C) () 2	2 1	0) 1	1 () (1 0
CVADYSFLYNSASFS	Spike25_V367F	0	C) ()	0	1	2	0	1	0	0	1	2	0	1	0	0	1	2	0	1	0	1	1	0	0	0	0	1	2	0	1	1	1	1 0	1 0) () 2	2 1	1 1		2 () () ()
TFKCYGVSPTKLNDL	Spike26wt	1	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0 0	1 () () () () () () () () 0
CFTNVYADSFVIRGD	Spike27wt	1	C) 1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0 0	/ () () () () 1) () () ()
EVRQIAPGQTGKIAD	Spike28wt	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 () ()	C) () () () () () (0 0	0
EVRQIAPGQTGNIAD	Spike28_K417N	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 (0 0	C) () () () () () () (0
EVRQIAPGQTGPIAD	Spike28_K417P	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 0) () () () () () () () () ()
YNYKLPDDFTGCVIA	Spike29wt	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 0) () () () () () () () () ()
WNSNNLDSKVGGNYN	Spike30wt	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 (0 0	C) () () () () () () (0
WNSKNLDSKVGGNYN	Spike 30_ N439K	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 (0 0	C) () () () () () () (0
WNSNKLDSKVGGNYN	Spike30_N440K	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 0) () () () () () () () () ()
YLYRLFRKSNLKPFE	Spike31wt	1	1	0	2	0	0	2	1	2	0	0	1	2	2	2	2	2	0	1	1	1	1	0	2	1	2	2	2	0	2	1	1	0	22	2	4 7	0) 1	0	ז 1	1 1	1_1	1
YRYRLFRKSNLKPFE	Spike31_L452R	1	1	0	2	0	0	2	1	2	0	0	1	2	2	2	2	2	0	1	1	1	1	0	2	1	2	2	2	0	2	1	2	0	22	2	2 3	() 1	0	1	1		1
RDISTEIYQVGSTPC	Spike32_A475V	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 (0 0	C) () () () () () () (0
RDISTEIYQAGSTPC	Spike32wt	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 (0 0	C) () () () () () () (0
RDISTEIYQAGNTPC	Spike32_S477N	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 () ()	0) () () () 0) () () (0
RDISTEIYQAGSKPC	Spike32_T478K	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 0) () () () () ()) () () (J 0
NGVEGFNCYFPLQSY	Spike33wt	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 (0 0	C) () () () () () () (0
NGVKGFNCYFPLQSY	Spike33_E484K	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 (0 0	C) () () () () () () (0
NGVQGFNCYFPLQSY	Spike33_E484Q	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 () ()	0) () () () 0) () () (0
NGVEGFNCYFPLRSY	Spike33_Q493R	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 (0 0	0) () () () ()) () () (0
NGAEGFNCYFPLQSY	Spike33_V483A	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 0) () () () () () () () () ()
GFQPTNGVGYQPYRV	Spike34wt	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 (0 0	0) () () () ()) () () (0
GFQPTYGVGYQPYRV	Spike34_N501Y	0	C) ()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 0	/ () () () () () () () () ()
VVLSFELLHAPATVC	Spike35wt	0	C) ()	0	2	1	0	0	0	2	1	1	0	2	0	0	0	2	0	0	0	1	1	0	0	0	1	2	1	0	0	2	1	0 0	/ () () 1	1 () () () () (1 0

Peptide name	Peptide sequence	Mutated peptide sequence	Mutation	B.1.526 (New York)	B.1.526.2 (USA)	B.1.427 (California/WestCoast)	B.1.429 (California/WestCoast)	P.1 (Brazilian (Manaus))	P.2 Brazilian (Rio de Janeiro)	B.1.525 (UK)	B.1.1.7 (UK)	B.1.351 (South Africa)	B.1.526.1 (USA)	B.1.617.1 (India)	B.1.617.2 (India)	B.1.526.3 (India)	Gaebleretal. (Nature, 2021)
Spike1 Spike1	MFVFLVLLPLVSSQC MEVELVLLPLVSSQC	MEVEFVLLPLVSSQC	L5F S13I	x	x	×	x										
spike2	VNLTTRTQLPPAYTN	VN TTRTQLPPAYTN	L18F					x									
Spike2	VNLTTRTQLPPAYTN	VNLRTRTQLPPAYTN	T19R												x	x	
spikez Spike2	VNLTTRTQLPPAYTN	VNLT RTQLPPAYTN	120N P26S					×									
Spike4	SVLHSTODLFLPFFS	SVLHSTRDLFLPFFS	Q52R							x							
Spike5	NVTWFHAIHVSGTNG	NVTWFH IHVSGTNG	A67V							x							
эрікер Spike6	TKRFDNPVLPFNDGV	TKRFANPVLPFNDGV	D80A							x	x	x					
spike6	TKRFDNPVLPFNDGV	TKREGNPVLPENDGV	D80G										x				
Spike7	YFASTEKSNIIRGWI	YFAS EKSNIIRGWI	T95I	x	x												
spike10 Spike10	CNDPFLGVYYHKNNK	CNDPFLGV_YHKNNK	Y144del					*		x	x		x				
Spike11	SWMESEFRVYSSANN	S MESEFRVYSSANN	W152C			x	x										
Spike11	SWMESEERVYSSANN	SWMESE RVYSSANN	F157S FR157-158del										x		×		
spike13	GKQGNFKNLREFVFK	GKQGNFKNLSEFVFK	R190S					×							^		
spike15	NLVRDLPQGFSALEP	NLVR LPQGFSALEP	D215G									x					
Spike17 Spike17	LLALHRSYLTPGDSS	LHRSYLTPGDSS	LLA241-243del D253G	x	x							x					
Spike24	RFASVYAWNRKRISN	RFASVYAWNRKRISN	R346S	^	-												x
spike25	CVADYSVLYNSASFS	CVADYSFLYNSASFS	V367F	а													x
Spike28 Spike28	EVRQIAPGQTGKIAD EVRQIAPGQTGKIAD	EVRQIAPGQTG IAD	K417N K417T					x				x					
Spike30	WNSNNLDSKVGGNYNV	NSKNLDSKVGGNYNN43	ж														x
Spike30	WNSNNLDSKVGGNYNV	NSN LDSKVGGNYNN44)K														x
ipike31 Snike32	RDISTEIYOAGSTPC	Y YRLFRKSNLKPFE RDISTEIYO/GSTPC	L452R A475V			x	x						x	x	x	x	x
spike32	RDISTEIYQAGSTPC	RDISTEIYQAGNTPC	S477N		x												x
spike32	RDISTEIYQAGSTPC	RDISTEIYQAGSKPC	T478K												x		
Spike33 Spike33	NGVEGENCYEPLQSY NGVEGENCYEPLQSY	NG EGFNCYFPLQSY W GENCYFPLQSY	V483A F484K	x				x	x	x		x					x
spike33	NGVEGENCYEPLQSYN	WGFNCYFPLQSYE4840	2											x		x	î
Spike33	NGVEGFNCYFPLQSY	NGVEGFNCYFPL SY	Q493R														x
Spike34 Spike38	GEQPTNGVGYQPYRVG NKKELPEQQEGRDIA	-QPTYGVGYQPYRVN501 NKKELPEQQEGRDI	A570D					x			x	x					
spike41	GTNTSNQVAVLYQDVG	NTSNQVAVLYQGV	D614G	x	×	x	x	x	x	x	×	x	×	x	x	x	
Spike44	RAGCLIGAEHVNNSY	RAGCLIGAE VNNSY	H655Y					x									
Spike46 Spike46	TQTNSPRRARSVASQ	TOTNSPRRARSVASQ TQTNSHRRARSVASQ	Q677H P681H							x	×						
pike46	TQTNSPRRARSVASQ	TQTNSRRRARSVASQ	P681R											x	x	x	
Spike47	SIIAYTMSLGAENSV	SIIAYTMSLG ENSV	A701V	x								x					
pikes8	NGLTVLPPLLTDEMI	NGL VLPPLLTDEMI	T859V								×		x				
spike60	WTFGAGAALQIPFAM	WTLGAGAALQIPFAM	F888L							x							
Spike64	GKLQDVVNQNAQALNG	LQ VVNQNAQALN	D950H										×				
spike64	GKLQDVVNQNAQALNG	LQDVVNQNA ALN	Q957R		x										x		
spike66	VLNDILSRLDKVEAE	VLNDILARLDKVEAE	S982A								x						
Spike69	SANLAATKMSECVLG	SANLAA KMSECVLG	T1027I					x									
spike79	GINASVVNIQKEIDR	GINAS VNIQKEIDR	V1176F					x	x		*						
lucleocapsid_1	MSDNGPQNQRNAPRIM	SINGPQNQRNAPRI	D3L								x						
lucleocapsid_1	MSDNGPQNQRNAPRIM MSDNGPQNQRNAPRIM	S_NGPQNQRNAPRI	D3del							x							
lucleocapsid_1	MSDNGPQNQRNAPRIM	SDNGPQNQRNALRI	P13L		x					*							
lucleocapsid_5	KEDLKFPRGQGVPIN	KEGLKFPRGQGVPIN	D63G												x		
lucleocapsid_5	KEDLKFPRGQGVPIN TNSSPDDOIGYVRRA	KEDLKF RGQGVPIN	P67S P80R					×								x	
lucleocapsid_8	PRWYFYYLGTGPEAGP	WYFYYLGTGPE G	A119S					<u>^</u>	x								
lucleocapsid_14	NSTPGSSRGTSPARMN	TLGSSRGTSPARM	P199L	x													
ucleocapsid_14 lucleocapsid_14	NSTPGSSRGTSPARMN NSTPGSSRGTSPARMN	TPGSRRGTSPARMS202	R203K		x			×	x		×						
lucleocapsid_14	NSTPGSSRGTSPARMN	TPGSSI/GTSPARMR203	M						-					x	x	x	
lucleocapsid_14	NSTPGSSRGTSPARMN	TPGSSRRTSPARM	G204R					×	x		x						
ucleocapsid_14	RLNQLESKMSGKGOOR	NQLESK SGKGQQ	M234I	x		x	x		x	x		x	x x				
lucleocapsid_16	RLNQLESKMSGKGQQR	NQLESKM GKGQQS235	F								x						
lucleocapsid_26	ADETQALPQRQKKQQA	ETQALPQRQKKQQ	D377Y											x	x	x	
ORF8 1	MKFLVFLGIITTVAA	MKFLVFLGII TVAA	5982A T11I	x	x						x		x				
DRF8_3	AFHQECSLQSCTQHQA	HQECSLQSC QHQ	T26I													x	
DRF8_3	AFHQECSLQSCTQHQA	HQECSLQSCT HQ	Q27X								x						
DRF8_4	LQSCTQHQPYVVDDPLC	SCIUNUPYVVDDP	Q27X								x					x	
DRF8_7	SKWYIRVGARKSAPL	SKWYIRVG RKSAPL	A51S										x				
DRF8_7	SKWYIRVGARKSAPL	SKWYIRVGA KSAPL	R52I								x						
0RF8 8	GARKSAPLIELCVDE	GORKSAPLIELCVDE GAIKSAPLIELCVDE	A515 R52I								×		x				
DRF8_10	EAGSKSPIQYIDIGN	EAGSKSPIQ IDIGN	Y73C								x						
0RF8_11	IQYIDIGNYTVSCLP	IQ IDIGNYTVSCLP	Y73C								×						
DRF8_14	EPKLGSLVVRCSFYE	KPKLGSLVVRCSFYE	E92K					x									
DRF3a_AB	VQIHTIDGSSGVVNP	VQIHTIDGS GVVNP	S253P					x									
ORF3a C	VQIHTIDVSSGVVNP	VQIHTIDVSPGVVNP	S253P					×									